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 CHAPTER 1  
 
INTRODUCTION 
 
1.1   PHARMACEUTICAL ASSAY METHODS AND AUTOMATION  
The SI analysis technique is now well known to have several advantages over 
conventional techniques followed in the past in the analytical laboratories. The proponents 
of this work have recently introduced FI analyzer and FI/SI analyzer systems in the 
research laboratory at the Department of Chemistry, College of Science, KFUPM the 
technique could be taught theoretically and practically as a part of a core course entitled 
"Instrumental Chemical Analysis" offered to our undergraduate students. Therefore, the 
newly provided methods could be applied as standard methods in the practical syllabi of 
instrumental chemical analysis in our Department. The implementation of SI analysis to 
modern analytical laboratories is an essential addition and a significant development to 
suit the new millennium expected changes and enhancements. Pharmaceutical industry is 
now growing in the Kingdom of Saudi Arabia with a special attention from the 
government and SI analysis would be a positive addition to meet the requirements. 
Environmental concerns and personnel safety as well as need for keeping operational cost 
to a minimum necessitate minimizing or eliminating such waste. Waste generation cannot 
be eliminated in the near future since traditional assay methods cannot economically be 
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 replaced. However, the SI technique is well suited to this goal, which is highly targeted by 
the government of the Kingdom.  
Traditionally, pharmaceutical analysis relies heavily on chromatography, yet the assay of 
pharmaceuticals also frequently requires the use of reagent-based techniques with 
spectrophotometric, fluorescence or electrochemical detection. Automation and 
miniaturization of these solution-based assays to make them fast and efficient are essential 
for many routine and research tasks in pharmaceutical laboratories. Ideally, instrumental 
techniques should be versatile, capable of accommodating a wide variety of assays 
without the need for system reconfiguration, and compatible with both optical and 
electrochemical detectors [1] 
Automation is a key demand of modern industrial-scale pharmaceutical analysis. New 
product development, validation of manufacturing process and routine quality control 
involve the analysis of a considerable amount of samples in order to ensure compliance of 
the formulations to the limits established by international authorities. Typical quality 
control tests that involve the analysis of many samples include [2]: 
(1) Assay of final products. 
(2) Dissolution profiles during production and validation of manufacturing processes. 
(3) Dosage uniformity tests. 
(4) In-process control especially during blending uniformity for solid and semi-solid 
formulations. 
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 1.2   OBJECTIVES 
  
1. To adopt novel methods for the assay of two compounds  
A. Ketoconazole (anti-fungal) by oxidizing it with cerium (IV) in sulfuric acid media 
and spectrophotometerically monitoring the oxidized form of the drug. 
B. Diclofenac sodium (anti-inflammatory) by oxidizing it with permanganate in 
sulfuric acid media and spectrophotometerically monitoring the appearance of the 
brown colored product resulting for quantitative assay of the drug. 
2.  SIA technique will be acquainted with and applied as a tool for the assay methods. 
3. Validation of the newly adopted methods will be carried out following USP 
monograph. 
4. Advantages of the newly adopted methods will be highlighted. 
 
 
 
 
 
 
 
 
 
 
 3
 1.3   FLOW INJECTION ANALYSIS 
 
Flow injection analysis (FIA) is a well-established automated technique with numerous 
and widespread applications in quantitative chemical analysis. In brief, a typical FI setup 
involves injection of a define volume of the sample into a moving stream of a solution 
which serves as a carrier and propellers the sample zone to a flow-through detector. 
Between the injection and detection points, the analyte of interest is chemically or 
physically transformed to detectable specie. FI is generally a simple and inexpensive 
technique employing common instrumentation such as peristaltic pumps and low-pressure 
injection valves. Compared to batch methods it offers increased sampling rate, lower 
reagents consumption, better precision and high versatility. The above-mentioned 
advantages of FI have led to a continuously Increasing interest in pharmaceutical analysis 
and quality control applications [3] The main chemical approach in applying FI to 
pharmaceutical analysis is through automation of derivatization reactions. On the other 
hand, more complicated procedures such as on-line solid-phase and solvent extraction, 
optical sensors, enzymatic reactions, etc., tend to attract scientists, based on the growing 
need for more sensitive and selective analytical methodologies. Although FI can be 
coupled to any detection system capable of flow-through operation covering a range that 
extends from simple LED-based optical systems to sophisticated mass spectrometers, 
UV–vis spectrophotometry seems to be the technique of choice for FI pharmaceutical 
applications. UV–vis spectrophotometry offers the advantages of simple, low cost 
instruments that are available at all laboratories. Running costs are minimal and no 
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 highly-skilled personnel are required for their operation. Another significant advantage is 
that pre-existing batch instruments can be easily converted to flow-through by either 
home-made or commercially available cells. Apart from the monograph published by 
Calatayud in 1996 [3], recent reviews on the application of FI to pharmaceutical analysis 
cover the topics of multicomponent determinations [4] and amperometric detection [5].  
 
1.3.1   Sequential Injection Analysis 
SIA (Sequential Injection) analysis is the second generation of FI (Flow Injection) 
techniques. It is a fully-automated approach to solution handling that allowing automating 
manual wet chemistry procedure in a rapid, precise, and efficient manner. Small solution 
zones are manipulated under controlled dispersion conditions in narrow bore tubing. 
While, like the first generation of FI technique, FI analysis, it is fundamentally dependent 
on the dispersion of zones in a flowing stream; conceptually, the practice of SI analysis is 
different from FI analysis. The upper diagram in figure 1 shows the main components of 
FI analyzer manifold and the lower diagram is for SI analyzer manifold. 
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Figure 1: The major components of FI and SI analyzers 
 
 
 
 
 
 6
 Consider a single line FI analysis experiment, where sample is injected into a carrier 
stream containing a reagent and sample is pumped into the sample loop of a two-position 
injection valve and the carrier is flowing constantly through the detector. The length of the 
sample loop determines the volume of sample injected. When the sample loop is loaded, 
the valve is switched on and the sample is introduced into a flowing carrier stream. The 
carrier carries the sample through the reactor (usually a reaction coil) to the detector. En 
route, the sample reacts with the reagent to form a detectable species that gives rise to a 
peak when it passes through the flow cell of the detector. A calibration curve is then used 
with the peak height, area or width to determine the concentration of the analyte in the 
solution. SI analysis, on the other hand, does not make use of an injection valve. Rather, a 
multi-positions selection valve replaces the injection valve. Usually, the peristaltic pump 
used in FI analyzer is replaced with a syringe pump in SI analyzer and an additional coil 
called the holding coil is added. To achieve the same measurement as described above, 
the syringe is filled with carrier solution containing the reagent. Then the selection valve 
is advanced to a port that is connected to the sample line. A small volume of sample is 
drawn up into the holding coil. The flow program determines the volume of sample; viz. 
the volume of sample that is drawn up by the pump into the holding coil. The selection 
valve is then advanced to a port that is connected to the detector, and the carrier transports 
the sample through the reactor to the flow cell of the detector. Again, a detectable species 
is formed and is registered as a peak by the detector. The concentration of the analyte in 
the solution is determined in a similar manner as for FI analysis.  
 7
 It is worth noting that at the moment of injection in FI analysis experiment, an un-
dispersed plug of sample is introduced into the carrier stream. In SI analysis, already 
during aspiration of the sample into the holding coil, dispersion begins to take place and 
the flow reversal, which takes place when the sample is sent off to the detector, plays a 
dramatic role in mixing the sample with the carrier. Fig. 2 depicts graphically what 
happens at the point of sample injection in an FI analyzer manifold (top) and during the 
flow reversal inherent to SI analyzer manifold (bottom) and a few seconds after the carrier 
has started to move the sample towards the detector. This phenomenon may cause SI 
analysis peak to look slightly different to FI analysis peak. As long as there has been good 
mixing between sample and reagent, this will not affect quantification because samples 
and standards are treated alike. In fact, it has been shown that the flow reversal contributes 
significantly to the mixing of zones. 
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Figure 2: Movement of injected solution through the channels of FI analyzer manifold 
(top) and SI analyzer (bottom) 
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 More often than not, instead of including the reagent in the carrier, an SI analysis 
experiment is expanded so that the reagent is loaded as a separate zone. In this case, the 
syringe is first filled with a simple carrier or buffer. After the sample zone has been drawn 
up into the holding coil, the selection valve is advanced to a port connected to a reagent 
reservoir and a small reagent zone is drawn up into the holding coil. Through this way, it 
is possible to construct a stack of well-defined zones, which can be mixed together to give 
a detectable species. You will appreciate that unlike FI analyzer, which requires re-
plumbing when a more complex chemical addition scheme is required, in SI analyzer, all 
that is, required is a change to the flow program. The manifold remains the same. The 
additional advantages of lowering reagent consumption and minimizing the production of 
potentially hazardous wastes are these important advantages of SI analysis.  
The other ports of the selection valve can be used for calibration standards, additional 
reagents and as locations where more sophisticated operations such as dilution, trace 
enrichment, and incubation of reactants can take place.  
A variation of SI analysis is sequential injection titration (SIT). In SIT, the reactor and 
detector in figure 1 are replaced with a stirred titration cell. Appropriate sensors, 
electrochemical or colorimetric, are placed in the titration cell, which acts as flow cell as 
well as titration chamber.  
SIA was developed by Ruzicka and Marshall at the University of Washington in response 
to an industry-initiated requirement for a more robust automated wet chemistry technique 
than FI analysis. At the Center for Process Analytical Science (CPAC), industry 
representatives challenged faculty and researchers to take FI analysis to the next level. 
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 Develop it to the point where its strengths were maintained and enhanced, but its 
limitations in the process environment were remedied. At other institutions, the problem 
was tackled by investigating the use of sensors. Other researchers explored 
miniaturization of FI analyzer.  
While SI analysis makes use of a simpler flow manifold (this is particularly so for multi 
component chemistries), development of the SI analysis method is not as straightforward. 
Careful attention needs to be given to the design of the measurement sequence to ensure 
that adequate zone penetration has taken place.  
SI analysis has several advantages over FI analysis. Reagent use is drastically reduced. 
Typical FI analysis experiments make use of at least 3mL of reagent per measurement. SI 
analysis typically makes use of maximum 50 µl.  
Flow manifolds are simple and robust typically comprising a pump, selection valve, and 
detector connected by tubing. The same manifold can be used for widely different 
chemistries simply by changing the flow program rather than the plumbing. Analyzer 
maintenance is therefore simplified. The selection valve replaces the injection valve and 
provides a means for selecting different sample streams and celebrants. This enables 
convenient automated calibration. Components used in a SI analyzer manifolds are 
amenable to laboratory, field, and plant operation. In addition to this, SI analysis enjoys 
all of the benefits of FI analysis. [6, 7, 8, and 9]  
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     Table 1: Major differences in the instrumentation of FIA and SIA 
SIA FIA 
It consist of a single channel, high 
precision bi-directional pump called 
the syringe pump ,a holding coil, 
multiselection valve, reaction coil and 
a detector 
It consists of a high quality 
multichannel peristaltic pump, an 
injection valve, a coiled reactor and a 
detector. 
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 1.3.2   The Advantages and Disadvantages of SIA 
While SIA makes use of a simpler flow manifold (this is particularly so for multi 
component chemistries), development of the SIA method is not as straight forward. 
Careful attention needs to be given to the design of the measurement sequence to ensure 
that adequate zone penetration has taken place. Accurate measurement of sample and 
reagent zones necessitates microprocessor control. Of course, once the method has been 
developed, the microprocessor ensures slavish repetition of the optimized sequence. 
Previous limitations associated with the use of syringe pumps (notably the need for a 
syringe fill cycle, and poor precision for sample volumes smaller than 10 µl), no longer 
apply. Global FIA has developed a new pump called the milliGATTM. That has all the 
advantages of a syringe pump but eliminates many of its limitations. In particular, the fill 
cycle and need to compromise syringe diameter in order to allow sufficient carrier volume 
for an experiment are conveniently overcome in the milliGATTM 
 
1.3.3   Advantages of SIA over FIA. 
1. Reagent use is drastically reduced. Typical FIA experiments make use of at least 
1mL of reagent per measurement. SIA typically makes use of 50 µl. This means 
that in a 24-hour period assuming one measurement per minute, the FIA analyzer 
would consume 1450 ml of reagent. The SIA analyzer would consume 72 ml. It has 
been noted that the most frequent reason for process analyzer failure is running out 
of reagents.  
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 2. Flow manifolds are simple and robust typically comprising a pump, selection valve, 
and detector connected by tubing. The same manifold can be used for widely 
different chemistries simply by changing the flow program rather than the 
plumbing. Analyzer maintenance is therefore simplified.  
3. The selection valve replaces the injection valve and provides a means for selecting 
different sample streams and calibrants. This enables convenient automated 
calibration.  
4. Components used in a SIA manifolds are amenable to laboratory, field, and plant 
operation. In addition to these, SIA enjoys all of the benefits of FIA 
 
1.4   CHEMOMETRICS 
Since its introduction in 1974 [10, 11], flow injection analysis (FIA), has developed 
rapidly and in various directions. Today, it is an internationally approved, routine method 
for the determination of quite a large number of analytes [12–16], and is also used in 
sample pre-treatment for selective detectors [17–19], process control [20,21], drug 
dissolution testing [22] and hyphenated separation techniques [23,24], to mention just a 
few further applications. New applications and technical advances of the technique are 
being continuously reported, and the number of published FIA papers now exceeds 
12,000 [25]. Its further development beyond the point of maturity and widespread 
acceptance has fostered versatile off-shoots, the most well known being sequential 
injection analysis [26] and lab-on-valve methodology [27]. These two advances show that 
FIA, not only provides a reproducible means of transporting diverse samples to any type 
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 of detector, but it is also an ideal technique for mechanising tedious manual sample 
handling steps in the analytical chain. Chemometric techniques, chemometrics, were 
introduced into analytical chemistry almost in parallel with flow injection analysis [28, 
29] and they have shown similar tendencies to FIA to increase in use and scope. Of most 
interest here is that chemometric approaches have been used in some cases during the 
development, refinement and validation of FIA methods, since they can save time during 
method development, and the treatment of data produced by some detectors in FIA 
systems more or less requires such approaches to yield analytically useful data. However, 
the majority of published FIA papers still report method development and detector signal 
treatments that do not employ any chemometrics at all. The reason for this is, perhaps, 
that most FIA practitioners have not yet discovered the inherent potential of the two 
scientific disciplines working hand in hand. This paper will therefore describe ways in 
which chemometrics can enhance the scope and power of FIA by considering a few 
representative cases where it is not immediately apparent that using chemometrics would 
improve performance. It is not intended to be a comprehensive review of the topic since 
several such reviews have already been presented [30, 31]. 
 
1.4.1   Definitions of chemometrics 
There are many different definitions of chemometrics, but the one introduced by Massart 
et al. [32] reads: “Chemometrics is a chemical discipline that uses mathematics, statistics 
and formal logic 
(a) To design or select optimal experimental procedures; 
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 (b) To provide maximum relevant chemical information by analysing chemical data; and 
(c) To obtain knowledge about chemical systems. 
This definition is attractive since it specifically recognises and includes the use of 
experimental design for system optimisation. Applying this definition to a typical FIA 
system we can see that there are (at least) three stages in method development where 
chemometrics could be involved: method optimisation, signal evaluation and the 
subsequent calibration procedures. 
 
1.4.2.   Experimental design versus one-variable at-a-time approaches 
“We optimized our FIA system. First, we established the optimum pH (6.5), and second, 
the lengths of the mixing coil (50 cm)”. Unfortunately, statements of this kind are 
frequently found in FIA papers. This commonly used optimisation strategy is based on 
varying one variable at a time. The obvious weakness of this strategy will be shown by a 
simple example. Assume that we first investigate the influence of pH on the response 
(peak height). We select a coil length of 40 cm and vary the pH of the reagent and carrier 
solutions in the range 3–7 and obtain a maximum response at pH 6.5, see Fig. 3a. This pH 
value is then taken as an “optimum” value and used throughout the subsequent method 
development process. Next, the effect of varying the coil length is investigated in the 
range 30–70 cm. A maximum appears when using a coil length of 50 cm, consequently 
the combination pH 6.5 and 50 cm will be our choice for obtaining the final optimum 
conditions. Fig. 4a and b illustrate how we indeed reach a maximum at pH 6.5, and a 
maximum when using a 50 cm coil, respectively. However, the position of the true 
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 maximum is given in Fig. 4c. This position, defining the ideal conditions as pH 7.8 and 
coil length 60 cm, would have been found if experiments had been based on techniques 
such as factorial design [33] or Simplex optimisation [34]. 
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Figure 3 Optimization of an FIA system using the one-variable-at-a-time approach (a) 
peak height plotted versus pH giving an “optimum” at pH 6.5 and (b) peak height versus 
coil length giving an “optimum” at 50 cm. 
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Figure 4 Optimization of an FIA system using the one-variable-at-a-time approach: (a) 
variation of pH using a coil length of 40 cm giving an “optimum” at pH 6.5; (b) variation 
of coil length at pH 6.5 giving an “optimum” at 50 cm; and (c) depiction of the “true” 
optimum at pH 7.8 uses a coil length of 60 cm 
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 1.4.2.1   Defining the response functions 
The fundamental question is: what is going to be optimised in the FIA system? The most 
commonly used response function is peak height, i.e. one often strives to maximise the 
detectability of the FIA system. Other relevant response functions are reagent 
consumption, response time and sample throughput. All these response functions are 
rather “coarse”. Any one with at least some experience of FIA method development 
knows that maximum peak heights are obtained when the sample volume is large, the 
carrier flow is high and the reagent flows are low. All this assumes that the chemical 
reactions involved are fast enough to reach completion by the time of detection. Another 
obvious consideration is that if minimal reagent consumption is desired, then this 
optimum will appear when the pumps are off, so this response function is useless when 
applied in isolation. Practical limits are always set for the controlled variables, and other 
phenomena may appear that have to be taken into account, for instance, baseline drift, 
deteriorating reproducibility of the peaks, and changes in peak shape, to mention just a 
few possible complications. Surprisingly little has been done to develop practical and 
imaginative response functions in this context. For example, the “efficiency” of an FIA 
system might be expressed as peak height per microliter injected sample. For most FIA 
systems the peak height increases almost linearly with the injected volume up to about 
100 µl, it then levels off and reaches a saturation value at about 400 µl. If this proposed 
response function is used, an optimum injection volume would probably fall in the range 
100–200 µl. Larger volumes will undoubtedly produce higher peaks, but the “efficiency” 
defined in this manner will drop dramatically. The lack of reliable but creative response 
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 functions might to some extent explain the low interest in using experimental design when 
developing new FIA methods. In this respect, some input might be obtained from papers 
describing the optimisation of chromatographic systems [35–38]. 
 
1.4.2.2   Variable selection 
The number of variables that have to be optimized in a typical FIA system is often very 
large. For instance, the standard manifold used for the determination of ammonia 
according to ISO [13] comprises at least 36 variables [39]. Even if each of these 36 
variables is varied at only two levels, high and low, there will be an incredible number of 
possible permutations of variables. If one experiment takes 1 min to perform and 
rebuilding the system to test a new permutation of variables also takes 1 min, it would 
then take 6,271,454 years to investigate all the possible permutations. Thus, it goes 
without saying that variables must be selected so that non-significant variables can be kept 
constant when optimising the remaining significant variables. Ideally, experimental design 
will be used in two steps. In the first step all variables will be included in a two-level 
Plackett–Burman design [40], to identify significant variables based on results obtained 
from a relatively limited number of experiments [41]. In the second step the significant 
variables will be investigated using, for instance, a full or reduced factorial design, 
keeping the non-significant variables at a constant level. 
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 1.4.3   Experimental Design 
Design of experiments was invented by Ronald A. Fisher in the 1920s and 1930s at 
Rothamsted Experimental Station, an agricultural research station 25 miles north of 
London. In Fisher’s first book on design of experiments1 he showed how valid 
conclusions could be drawn efficiently from experiments with natural fluctuations such as 
temperature, soil conditions, and rain fall, that is, in the presence of nuisance variables. 
The known nuisance variables usually cause systematic biases in groups of results (e.g., 
batch-to-batch variation). The unknown nuisance variables usually cause random 
variability in the results and are called inherent variability or noise. Although the 
experimental design method was first used in an agricultural context, the method has been 
applied successfully in the military and in industry since the 1940s. Besse Day, working at 
the U.S. Naval Experimentation Laboratory, used experimental design to solve problems 
such as finding the cause of bad welds at a naval shipyard during World War II. George 
Box, employed by Imperial Chemical Industries before coming to the United States, is a 
leading developer of experimental design procedures for optimizing chemical processes. 
W. Edwards Deming taught statistical methods, including experimental design, to 
Japanese scientists and engineers in the early 1950s2 at a time when “Made in Japan” 
meant poor quality. Genichi Taguchi, the most well known of this group of Japanese 
scientists, is famous for his quality improvement methods. One of the companies where 
Taguchi first applied his methods was Toyota. Since the late 1970s, U.S. industry has 
become interested again in quality improvement initiatives, now known as “Total 
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 Quality” and “Six Sigma” programs. Design of experiments is considered an advanced 
method in the Six Sigma programs, which were pioneered at Motorola and GE. 
 
1.4.3.1   Fundamental Principles 
The fundamental principles in design of experiments are solutions to the problems in 
experimentation posed by the two types of nuisance factors and serve to improve the 
efficiency of experiments. Those fundamental principles are 
• Randomization 
• Replication 
• Blocking 
• Orthogonality 
• Factorial experimentation 
Randomization is a method that protects against an unknown bias distorting the results of 
the experiment. 
An example of a bias is instrument drift in an experiment comparing a baseline procedure 
to a new procedure. If all the tests using the baseline procedure are conducted first and 
then all the tests using the new procedure are conducted, the observed difference between 
the procedures might be entirely due to instrument drift. To guard against erroneous 
conclusions, the testing sequence of the baseline and new procedures should be in random 
order such as B, N, N, B, N, B, and so on. The instrument drift or any unknown bias 
should “average out.” Replication increases the sample size and is a method for increasing 
the precision of the experiment. Replication increases the signal-to-noise ratio when the 
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 noise originates from uncontrollable nuisance variables. A replicate is a complete 
repetition of the same experimental conditions, beginning with the initial setup. A special 
design called a Split Plot can be used if some of the factors are hard to vary. 
Blocking is a method for increasing precision by removing the effect of known nuisance 
factors. An example of a known nuisance factor is batch-to-batch variability. In a blocked 
design, both the baseline and new procedures are applied to samples of material from one 
batch, then to samples from another batch, and so on. The difference between the new and 
baseline procedures is not influenced by the batch-to-batch differences. Blocking is a 
restriction of complete randomization, since both procedures are always applied to each 
batch. Blocking increases precision since the batch-to-batch variability is removed from 
the “experimental error. 
Orthogonality in an experiment results in the factor effects being uncorrelated and 
therefore more easily interpreted. The factors in an orthogonal experiment design are 
varied independently of each other. The main results of data collected using this design 
can often be summarized by taking differences of averages and can be shown graphically 
by using simple plots of suitably chosen sets of averages. In these days of powerful 
computers and software, orthogonality is no longer a necessity, but it is still a desirable 
property because of the ease of explaining results. 
Factorial experimentation is a method in which the effects due to each factor and to 
combinations of factors are estimated. Factorial designs are geometrically constructed and 
vary all the factors simultaneously and orthogonally. Factorial designs collect data at the 
vertices of a cube in p-dimensions (p is the number of factors being studied). If data are 
collected from all of the vertices, the design is a full factorial, requiring 2p runs. Since the 
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 total number of combinations increases exponentially with the number of factors studied, 
fractions of the full factorial design can be constructed. As the number of factors 
increases, the fractions become smaller and smaller (1/2, 1/4, 1/8, 1/16,..).Fractional 
factorial designs collect data from a specific subset of all possible vertices and require (2p-
q) runs, with 2-q being the fractional size of the design. If there are only three factors in the 
experiment, the geometry of the experimental design for a full factorial experiment 
requires eight runs, and a one-half fractional factorial experiment (an inscribed 
tetrahedron) requires four runs (Fig. 5). 
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Figure 5 Full factorial and one-half factorial in three dimensions 
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 Factorial designs, including fractional factorials, have increased precision over other types 
of designs because they have built-in internal replication. Factor effects are essentially the 
difference between the average of all runs at the two levels for a factor, such as “high” 
and “low.” Replicates of the same points are not needed in a factorial design, which seems 
like a violation of the replication principle in design of experiments. However, half of all 
the data points are taken at the high level and the other half are taken at the low level of 
each factor, resulting in a very large number of replicates. Replication is also provided by 
the factors included in the design that turn out to have nonsignificant effects. Because 
each factor is varied with respect to all of the factors, information on all factors is 
collected by each run. In fact, every data point is used in the analysis many times as well 
as in the estimation of every effect and interaction. Additional efficiency of the two-level 
factorial design comes from the fact that it spans the factor space, that is, puts half of the 
design points at each end of the range, which is the most powerful way of determining 
whether a factor has a significant effect. 
 
1.4.3.2   Uses  
The main uses of design of experiments are 
• Discovering interactions among factors 
• Screening many factors 
• Establishing and maintaining quality control 
• Optimizing a process, including evolutionary operations (EVOP) 
• Designing robust products 
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 Interaction occurs when the effect on the response of a change in the level of one factor 
from low to high depends on the level of another factor. In other words, when an 
interaction is present between two factors, the combined effect of those two factors on the 
response variable cannot be predicted from the separate effects. The effect of two factors 
acting in combination can either be greater (synergy) or less (interference) than would be 
expected from each factor separately. 
Frequently there is a need to evaluate a process with many input variables and with 
measured output variables. This process could be a complex computer simulation model 
or a manufacturing process with raw materials, temperature, and pressure as the inputs. A 
screening experiment tells us which input variables (factors) are causing the majority of 
the variability in the output (responses), i.e., which factors are the “drivers.” A screening 
experiment usually involves only two levels of each factor and can also be called 
characterization testing or sensitivity analysis. 
A process is “out of statistical control” when either the mean or the variability is outside 
its specifications. When this happens, the cause must be found and corrected. The cause is 
found efficiently using an experimental design similar to the screening design, except that 
the number of levels for the factors need not be two for all the factors. 
Optimizing a process involves determining the shape of the response variable. Usually a 
screening design is performed first to find the relatively few important factors. A response 
surface design has several (usually three or four) levels on each of the factors. This 
produces a more detailed picture of the surface, especially providing information on 
which factors have curvature and on areas in the response where peaks and plateaus occur. 
The EVOP method is an optimization procedure used when only small changes in the 
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 factors can be tolerated in order for normal operations to continue. Examples of EVOP are 
optimizing the cracking process on crude oil while still running the oil refinery or tuning 
the welding power of a welding robot in a car manufacturing assembly line. 
Product robustness, pioneered by Taguchi, uses experimental design to study the response 
surfaces associated with both the product means and variances to choose appropriate 
factor settings so that variance and bias are both small simultaneously. Designing a robust 
product means learning how to make the response variable insensitive to uncontrollable 
manufacturing process variability or to the use conditions of the product by the customer. 
 
1.4.3.3   Mathematical Formulation and Terminology 
The input variables on the experiment are called factors. The performance measures 
resulting from the experiment are called responses. Polynomial equations are Taylor 
series approximations to the unknown true functional form of the response variable. An 
often quoted insight of George Box is, “All models are wrong. Some are useful.” The 
trick is to have the simplest model that captures the main features of the data or process. 
The polynomial equation, shown to the third order in Eq. 1 Scheme 1 used to model the 
response variable Y as a function of the input factors X’s is 
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Scheme 1: The polynomial equation used to model the response variable Y as a function 
of the input factors X’s where: 
β0 = the overall mean response, 
βI = the main effect for factor (i = 1, 2, ... , p), 
βij = the two-way interaction between the ith and jth factors, and 
βijk = the three-way interaction between the ith, jth, and kth factors. 
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 Usually, two values (called levels) of the X’s are used in the experiment for each factor, 
denoted by high and low and coded as 11 and 21, respectively. A general recommendation 
for setting the factor ranges is to set the levels far enough apart so that one would expect 
to see a difference in the response but not so far apart as to be out of the likely operating 
range. The use of only two levels seems to imply that the effects must be linear, but the 
assumption of monotonicity (or nearly so) on the response variable is sufficient. At least 
three levels of the factors would be required to detect curvature. 
Interaction is present when the effect of a factor on the response variable depends on the 
setting level of another factor. Graphically, this can be seen as two nonparallel lines when 
plotting the averages from the four combinations of high and low levels of the two factors. 
The βij terms in Eq. 1 account for the two-way interactions. Two-way interactions can be 
thought of as the corrections to a model of simple additivity of the factor effects, the 
model with only the βI terms in Eq. 1. The use of the simple additive model assumes that 
the factors act separately and independently on the response variable, which is not a very 
reasonable assumption. 
Experimental designs can be categorized by their resolution level. A design with a higher 
resolution level can fit higher-order terms in Eq. 1 than a design with a lower resolution 
level. If a high enough resolution level design is not used, only the linear combination of 
several terms can be estimated, not the terms separately. The word “resolution” was 
borrowed from the term used in optics. Resolution levels are usually denoted by Roman 
numerals, with III, IV, and V being the most commonly used. To resolve all of the two-
way interactions, the resolution level must be at least V. Four resolution levels and their 
meanings are given in Table 2. 
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              Table 2 Resolution levels and their meanings 
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 1.4.3.4   Number of Runs need for Factorial Experimental Design 
Many factors can be used in a screening experiment for a sensitivity analysis to determine 
which factors are the main drivers of the response variable. However, as noted earlier, as 
the number of factors increases, the total number of combinations increases exponentially. 
Thus, screening studies often use a fractional factorial design, which produces high 
confidence in the sensitivity results using a feasible number of runs. 
Fractional factorial designs yield polynomial equations approximating the true response 
function, with better approximations from higher resolution level designs. The minimum 
number of runs needed for Resolution IV and V designs is shown in Table 3 as a function 
of the number of factors in the experiment. 
There is a simple relationship for the minimum number of runs needed for a Resolution 
IV design: round up the number of factors to a power of two and then multiply by two. 
The usefulness of Table 3 is to show that often there is no penalty for including more 
factors in the experiment. For example, if 33 factors are going to be studied already, then 
up to 64 factors can be studied for the same number of runs, namely, 128. It is more 
desirable to conduct a Resolution V experiment to be able to estimate separately all the 
two-way interactions. However, for a large number of factors, it may not be feasible to 
perform the Resolution V design. Because the significant two-way interactions are most 
likely to be combinations of the significant main effects, a Resolution IV design can be 
used first, especially if it is known that the factors have monotonic effects on the response 
variable. Then a follow-up Resolution V design can be performed to determine if there are 
any significant two-way interactions using only the factors found to have significant 
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 effects from the Resolution IV experiment. If a factorial design is used as the screening 
experiment on many factors, the same combinations of factors need not be replicated, 
even if the simulation is stochastic. Different design points are preferable to replicating 
the same points since more effects can be estimated, possibly up to the next higher 
resolution level. 
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Table3.Two-level designs: minimum number of runs as a 
                           function of number of factors 
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 1.4.3.5   Implementation  
The main steps to implement an experimental design are as follows. Note that the subject 
matter experts are the main contributors to the most important steps, i.e., 1–4, 10, and 12. 
1. State the objective of the study and the hypotheses to be tested.  
2. Determine the response variable( s) of interest that can be measured.  
3. Determine the controllable factors of interest that might affect the response 
variables and the levels of each factor to be used in the experiment. It is better to 
include more factors in the design than to exclude factors, that is, prejudging them 
to be nonsignificant.  
4. Determine the uncontrollable variables that might affect the response variables, 
blocking the known nuisance variables and randomizing the runs to protect against 
unknown nuisance variables.  
5. Determine the total number of runs in the experiment, ideally using estimates of 
variability, precision required, size of effects expected, etc., but more likely based 
on available time and resources. Reserve some resources for unforeseen 
contingencies and follow-up runs. Some practitioners recommend using only 25% 
of the resources in the first experiment.  
6. Design the experiment, remembering to randomize the runs.  
7. Perform a pro forma analysis with response variables as random variables to check 
for estimability of the factor effects and precision of the experiment.  
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 8. Perform the experiment strictly according to the experimental design, including 
the initial setup for each run in a physical experiment. Do not swap the run order 
to make the job easier.  
9. Analyze the data from the experiment using the analysis of variance method 
developed by Fisher.  
10. Interpret the results and state the conclusions in terms of the subject matter.  
11. Consider performing a second, confirmatory experiment if the conclusions are 
very important or are likely to be controversial.  
12. Document and summarize the results and conclusions, in tabular and graphical 
form, for the report or presentation on the study. [42] 
 
1.4.4   Simplex Optimization 
The simplex method is based on an initial design of k+1 trials, where k is the number of 
variables. A k+1 geometric figure in a k-dimensional space is called a simplex. The 
corners of this figure are called vertices. A simplex is a geometric figure having one more 
vertex than its number of factors. Therefore a simplex in one dimension is a line, in two 
dimensions a triangle, in three dimensions a tetrahedron, see figure 6, and in multiple 
dimensions a hyper-tetrahedron. A geometric interpretation is difficult with more 
variables, but the basic mathematical approach outlined below can handle the search for 
optimum conditions (Otto, 1999). 
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 Figure 6 Geometric interpretation of lower dimensional simplex. The shapes of the 
simplex in a one, a two and a three variable search space, are a line, a triangle or a 
tetrahedron. 
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 1.4.4.1   The basic simplex method 
The basic simplex method is easy to understand and apply. The optimization begins with 
the initial trials. The trial conditions are spread out efficiently. These initial trials form the 
first simplex. The number of initial trials is equal to the number of control variables plus 
one. With two variables, the first simple design is based on three trials for three variables 
it is four trials, etc. This number of trials is also the minimum for defining a direction of 
improvement. Therefore, it is a time saving and economical way to start an optimization 
project. After the initial trials, the simplex process is sequential, with the addition and 
evaluation of one new trial at a time. The simplex searches systematically for the best 
levels of the control variables. The optimization process ends when the optimization 
objective is reached or when the responses cannot be further improved, see figure 7. 
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Figure 7 Basic simplex rules 
The calculations in the basic simplex algorithm are outlined in the flow chart. For each 
simplex, the following labels are used: W for the least favorable trial or the trial being 
rejected, B for the most favorable trial and Nw FOR the second least favorable trial (i.e. 
next to worst).  
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 The first rule is to reject the trial with the least favourable response value in the current 
simplex. A new set of control variable levels is calculated, by reflection into the control 
variable space opposite the undesirable result. This new trial (R) replaces the least 
favourable trial in the next simplex. This leads to a new least favourable response in the 
simplex that, in turn, leads to another new trial, and so on. Through this, the simplex will 
mes very large. These disadvantages can be 
ircumvented if the step width is tuneable, as with in the variable-size simplex or 
odified simplex method (Otto, 1999). 
move steadily towards more favourable conditions away from the least favourable 
conditions 
These steps are repeated until the simplex begins to rotate around the optimum or the 
response satisfies the experimenters´ needs (1996; Otto, 1999), se figure 8. The fixed step 
width of the fixed size simplex might lead to problems if the step width chosen is either 
too large or too small. In the first case, the optimum might be missed and in the latter the 
number of experiments required beco
c
m
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Figure 8 Illustration of a simplex path with two variables. After three initial trials the 
corners of the triangle are classified as W for the least favorable trial or the trial being 
jected, B for the most favorable trial and Nw for the second least favorable trial (i.e. 
ext to worst). Then the next trial 4 (R) is calculated and performed. 
 
re
n
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 1.4.4.2   The modified simplex method 
The modified simplex method has much in common with the basic method, but can adjust 
its shape and size depending on the response in each step. Several new rules are added to 
the basic simplex rules. These rules make the simplex expand, in a direction of more 
favourable conditions, or contract if a move was taken in a direction of less favourable 
 sequence are easy to show for control variables (the response is 
sion (E) and contraction (C- and 
+) of the reflected vertices, see figures 9 and 10. [43] 
conditions. 
The procedure for expansion and contraction enable the modified simplex both to 
accelerate along a successful track of improvement and to home in on the optimum 
conditions. Therefore the modified simplex will usually reach the optimum region quicker 
than the basic method will and will pinpoint the optimum levels more closely. Moves in a 
typical optimization
shown separately). 
The degree of contraction depends on how unfavourable the new response is. With the 
modified simplex, the step width is changed by expan
C
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Figure 9 Illustration of the different moves with the modified simplex method, adding the 
xpansion and contraction of the reflected vertices 
 
e
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igure 10 An example of a typical optimization sequence with modified simplex method. 
hange in the levels for two control variables. 
 
 
 
F
C
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 1.4.4.3   MultiSimplex 
The MultiSimplex program is designed as a true multivariate non-linear optimization tool 
that combines the modified simplex method [44] with the fuzzy set theory [45] by means 
of the membership functions or the point response measure called the aggregated value or 
membership. The advantage of MultiSimplex is that it allows simultaneous optimization 
of several response signals and considers the interaction among variables. MultiSimplex 
optimization is easy to follow and has been already used in some analytical application. 
To do the MultiSimplex optimization, the variables, the range of each variable and the 
responses that are going to be followed are defined. Then MultiSimplex suggests a K + 1 
number of experiments; where K is the number of variables to be studied. Once the 
experiments are carried out, the answers of the experiments are introduced and 
MultiSimplex suggests one new experiment. The process is continued until the optimum 
conditions are reached. In order to measure the closeness to the optimum, MultiSimplex 
makes use of the “membership value” [44]. This value ranges from 0 to l and takes into 
account the results of all responses considered in the optimization. Optimized conditions 
are achieved when the membership value is close to 1. The optimization procedure 
includes a re-evaluation rule that means, for every certain number of experiments, a 
revious trial is repeated experimentally. p
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 1.5   METHODS VALIDATION 
The FDA in its most recent publication, Guidance for Industry on Analytical Procedures 
llection by the applicant of the 
iewed and approved by the 
not complete until the methods are 
and Methods Validation, states: 
Methods validation is the process of demonstrating that analytical procedures are 
suitable for their intended use. The methods validation process for analytical 
procedures begins with the planned and systematic co
validation data to support analytical procedures. [46] 
What the FDA does not say is that the actual validation component of the methods 
validation process should be the culmination of a well-organized, well-planned, and 
systematically executed process that includes method development, prevalidation studies, 
and finally, methods validation itself. Gone are the days where one did methods 
development/validation concurrently. Validation is the end game where few surprises and 
deviations are expected. Validation is executed with a formal, approved and signed 
methods validation protocol in place which has been reviewed by the quality assurance 
(QA) unit. Validation is complete when you: 
(1) Demonstrate that you have met all the acceptance criteria. 
(2) Clearly document the results in a CGMP compliant fashion. 
(3) Show how you met the acceptance criteria in a final methods validation report, 
including references to raw data, all of which have been rev
appropriate personnel including peers, management, and QA. 
Some would even argue that the validation process is 
successfully transferred to their end-user laboratories. 
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 This sounds like a daunting task. And to be completely honest—it is. There is nothing 
trivial or easy about methods validation. It takes time, resources, and rarely goes as easy 
as you think it’s going to go. Methods validation is part science, part art, and a lot of 
ypothesized that many of the problems discovered 
uring root-cause analysis of out-of-specification results (OOS) are a direct result of 
dated methods. 
The following are typical analytical performance characteristics which may be tested 
dur  lidation: 
• 
 and Intermediate precision 
bookkeeping and accounting. To be brutally honest, too few laboratories do a very good 
job executing all the components. 
Due to the magnitude of the task, the time, and the perceived costs, many laboratories try 
to cut corners. At a minimum, this results in deviations from the protocol which no longer 
can be “arm waved” away. The FDA expects you to scientifically address failures as you 
would any other laboratory investigation. This takes more time and effort and often results 
in delays in the validation timeline. In the worst case, you end up validating a method that 
is transferred to quality control (QC) labs worldwide, and ends up being the root cause of 
untold laboratory investigations. It is h
d
poorly or partially vali
 
1.5.1   Approach  
ing methods va
Accuracy 
• Precision 
o Repeatability
• Specificity 
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 • Detection limit 
ation limit 
ies 
• 
• formation 
o Degradation pathways (if known) 
ion of some characteristic is given in the following subsections. 
 straight line with a given slope 
• Quantit
• Linearity 
• Range 
• Robustness 
• System suitability determination 
• Forced degradation stud
• Solution stability studies 
• Filter retention studies 
Extraction efficiency studies 
Additional methods validation in
o Representative instrument output 
o Representative calculations 
o Listing and characterization of known impurities 
A more detailed definit
 
1.5.1.1   Accuracy 
Accuracy is the nearness of a measured value to the true or accepted value. It provides an 
indication of any systematic error or bias in the method. For an unbiased method, a 
theoretical plot of measured value versus true value can be described by a mathematical 
function. In the pharmaceutical industry, this is typically a
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 and zero intercept. It follows that the accuracy of a biased method varies with the analyte 
concentration according to the types of systematic errors. 
During the validation, accuracy is determined by measuring the recovery of the active 
component from a drug product matrix or by directly measuring the active pharmaceutical 
ingredient (API). Typically studies involve spiking the drug product placebo matrix with 
API in amounts equal to the nominal finished dosage strength. This spiking is either by 
dding of standard solutions or dry spiking API into the matrix followed by complete 
ability is performed 
s on a different day 
sing different conditions and different instruments. Recovery values are calculated and 
mparison is made to the first analyst’s results. 
 
a
mixing. 
 
1.5.1.2   Precision 
Precision consists of two components: repeatability and intermediate precision. 
Repeatability is the variation experienced by a single analyst on a single instrument. 
Repeatability does not distinguish between variation from the instrument or system alone 
and from the sample preparation process. During the validation, repeat
by analyzing multiple replicates of an assay composite sample by using the analytical 
method. The recovery value is calculated and reported for each value. 
Intermediate precision refers to variations within a laboratory such as different days, with 
different instruments, and by different analysts. This was formerly known as ruggedness. 
During the validation, a second analyst repeats the repeatability analysi
u
reported. A statistical co
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 1.5.1.3   Specificity 
Specificity is the ability to assess unequivocally the analyte in the presence of components 
that may be expected to be present such as impurities, degradation products, and 
excipients. There must be inarguable data for a method to be specific. Specificity = 
measures only the desired component without interference from other species that might 
 interferences occur. 
e 
atrix), yet not be selective (e.g., doesn’t separate and identify all components present). 
s that only determine if 
the analyte concentration is above or below a specification limit). 
be present; separation is not necessarily required. 
To determine specificity during the validation blanks, sample matrix (placebo), and 
known related impurities are analyzed to determine whether
Specificity is also demonstrated during forced degradation studies. 
The term “selectivity” is sometimes used interchangeably with specificity. Technically, 
however, there is a difference. Selectivity is defined as the ability of the method to 
separate the analyte from other components that may be present in the sample, including 
impurities. Selectivity is separate and shows every component in the sample. Therefore, 
one could have a method that is specific, yet it may not be selective. For instance, an ion 
selective electrode may be specific (e.g., is used to measure a single species in sampl
m
 
1.5.1.4   Detection Limit 
The detection limit (DL) or limit of detection (LOD) of an individual procedure is the 
lowest amount of analyte in a sample that can be detected but not necessarily quantitated 
as an exact value. The LOD is a parameter of limit tests (i.e., test
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 In analytical procedures such as HPLC that exhibit baseline noise, the LOD can be based 
on a signal-to-noise (S/N) ratio (3:1), which is usually expressed as the concentration 
(e.g., percentage, parts per billion) of analyte in the sample. There are several ways in 
which it can be determined, but it usually involves injecting samples, which generate an 
S/N of 3:1, and estimating the DL. 
 
1.5.1.5   Quantitation Limit 
The quantitation limit (QL) or limit of quantitation (LOQ) of an individual analytical 
procedure is the lowest amount of analyte in a sample that can be quantitatively 
determined with suitable precision and accuracy. The quantitation limit is a parameter of 
quantitative assays for low concentrations of compounds in sample matrices and is used 
particularly for the determination of impurities and/or degradation products. It is usually 
expressed as the concentration (e.g., percentage, parts per million) of analyte in the 
sample. 
For analytical procedures such as HPLC that exhibit baseline noise, the LOQ is generally 
estimated from a determination of S/N ratio (10:1) and is usually confirmed by injecting 
standards which give this S/N ratio and have an acceptable percent relative standard 
deviations (%RSDs) as well. 
 
1.5.1.6   Linearity 
Linearity evaluates the analytical procedure’s ability (within a give range) to obtain a 
response that is directly proportional to the concentration (amount) of analyte in the 
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 sample. If the method is linear, the test results are directly or by well-defined 
mathematical transformation proportional to the concentration of analyte in samples 
within a given range. Linearity is usually expressed as the confidence limit around the 
slope of the regression line. The line is calculated according to an established 
mathematical relationship from the test response obtained by the analysis of samples with 
varying concentrations of analyte. Note that this is different from range (sometimes 
referred to as linearity of method) which is evaluated using samples and must encompass 
the specification range of the component assayed in the drug product. 
During validation, linearity may be established for all active substances, preservatives, 
and expected impurities. Evaluation is usually performed on standards. 
 
1.5.1.7   Range 
Range is defined as the interval between the upper and lower concentrations (amounts) of 
analyte in the sample (including these concentrations) for which it has been demonstrated 
that the analytical procedure has a suitable level of precision, accuracy, and linearity. 
Range is normally expressed in the same units as test results (e.g., percent, parts per 
million) obtained by the analytical method. 
During validation, range (sometimes referred to as linearity of method) is evaluated using 
samples (usually spiked placebos) and must encompass the specification range of the 
component assayed in the drug product. 
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 1.5.1.8   Robustness 
Robustness is defined as the measure of the ability of an analytical method to remain 
unaffected by small but deliberate variations in method parameters (e.g., pH, mobile-
phase composition, temperature, and instrument settings) and provides an indication of its 
reliability during normal usage. This is an important parameter with respect to the 
transferability of the method following validation. 
Determining robustness is a systematic process of varying a parameter and measuring the 
effect on the method by monitoring system suitability and/or the analysis of samples. It is 
part of the formal methods validation process. [47] 
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CHAPTER 2 
 
EXPERIMENTAL  
 
The ultimate objective of this research is to develop automated SIA methods that can be 
applied directly in the pharmaceutical industry therefore, it’s highly imperative that the 
chemistry of the proposed methods be aligned with already published chemistry for the 
drug analysis of Ketoconazole and Diclofenac sodium. The computer flow programs for 
these SIA methods were written, optimized using the univariate method of approach, 
empirical approach and chemometrics optimization using the MultiSimplex® for 
Windows version 2.1.3 (2001) supplied by Grabitech Solutions AB (Publ), Sundsvall, 
Sweden for chemometric optimization  
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2.1   CHEMICAL AND REAGENTS PREPARATIONS 
 
 
The reagents and solution for the adapted SIA methods were prepared using analar grade 
chemicals according to the method procedure. Distilled water used was double distilled 
and deionized. 
 
2.2   INSTRUMENTATION 
 
The manifold to be used in this method consists of SIA combined with a fiber optic 
spectrometer. The SIA system is the FIALab 3500 (Medina, WA USA). It is composed of 
a syringe pump, a multi-position valve, a Z-flow cell with SMA fiber optic connectors as 
well as pump tubing and PC. The Syringe Pump is 24,000 steps with an optical encoder 
feedback and 1.5 seconds to 20 minutes per stroke of 2.5 ml size. It is > 99% accuracy at 
full stroke. The volume capacity of syringe is 2500 µl. The Multi-Position Valve has eight 
ports with a standard pressure of 250 psi (gas)/600 psi (liquid); zero dead volume; 
chemically inert; port selection is usually done using the software program. The Z-Flow 
Cell is 10 mm path length plexiglass compatible with standard SMA terminated fiber 
optics was used. Pump Tubing of 0.30” ID Teflon type supplied by Upchurch Scientific, 
Inc. (Oak Harbor, WA, USA) was used for connecting the different units; and making 
both the holding coil (190 cm long) and the reaction coil (190 cm long). The fiber optic 
spectrometer is composed of a light source, 200 micron fiber optic connectors and a 
detector. The light source is LS-1 Tungsten Halogen (Ocean Optics, USA) optimized for 
VIS-NIR (360nm-2µm) wavelength range. The detector is USB2000 Spectrometer 
(Ocean Optics, USA) adapted to 200-1100 nm wavelength range. The SIA manifold is 
illustrated below Fig 11 and Fig 12. 
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Figure11. Schematic of SIA manifold used for the proposed SIA methods for 
Ketoconazole, Diclofenac determination. 
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Syringe pump
Holding coil
Light source UV/VIS spectrophotometer Lab-on-Valve mounted on
a 6-port multi-position valve
Flow-cell
Rotating selector slot
Fiber optic
to the Light
source
Fiber optic to the Absorption or
Fluorescence Detector
 
Figure 12: SIA instrumentation showing the channeled multiselection valve, fiber optic 
     Cables for light source and computer processor 
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2.3   SOFTWARE PACKAGE 
FIALab® for Windows version 5.0 from FIAlab Co. (Medina, WA USA) for 
programming and controlling the SI analyzer manifold. OOIBase® version 2.0.1.2, driver 
version 4.07.00 (2002), supplied from Ocean Optic, Inc for acquisition and treatment of 
the spectrophotometric data 
 SigmaPlot® for Windows version 9.01 from Systat Software, Inc. for data interpolation 
and constructing surface plots. 
MultiSimplex® for Windows version 2.1.3 (2001) supplied by Grabitech Solutions AB 
(Publ), Sundsvall, Sweden for chemometric optimization.  
SigmaStat® supplied from Jandel Scientific Corporation (93/ 1994) for chemometric 
calculations. SPSS® for Windows version 10.0.1 for statistical analysis.  
Minitab software for analysis of variance (ANOVA) 
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2.4   THE SEQUENTIAL STEPS FOR ANALYSIS 
The procedure steps followed for the assay of ketoconazole and diclofenac in 
pharmaceutical preparations is described as under utilizing the Alitea FIALab software 
for controlling different SIA components.  Similar programs for preliminary 
investigations and optimization were designed similarly as shown in Appendices I to III.    
 
I. Water will be linked to the SP through the in-position mode to push reagents to the 
required part of the SI analyzer manifold. 
II. Standard solutions will be linked to the MPV through ports 2, 3, 4 and 5. 
III. The syringe will fill with 5000 µl of water by directing the two-way valve to the in-
position mode with flow rate of 50µl/s 
IV. Tubes will be loaded with their respective reagents by performing aspiration runs and 
directing the two-way valve to the out-position mode with flow rate of 50µl/s 
V. With a different flow rate, the syringe will be dispensing 2000 µl.   
VI. The appropriate volume of the drugs (Ketoconazole or Diclofenac) and cerium (IV) in 
µl will be sequentially aspirated into the HC.  
VII. The appropriate volume of product will be dispensed at the required flow rate to the 
Z and, simultaneously, the reference and absorbance scan will be carried out. Maximum 
value of the monitor peak will record as the value of the absorbance of the drug solution  
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2.5   SIA INSTRUMENT VALIDATION 
Validation of the SIA system was carried out by conducting the Operation Qualification 
(OQ) using potassium permanganate as a stable well known standard. The Operation 
Qualification (OQ) was conducted to trust that all data generated is precise and accurate.  
 
2.5.1   Preparation of Permanganate Standard Solutions 
 
A standard solution was prepared by dissolving exactly about 3.5 g of dried potassium 
permanganate (P-279 Lot 746030 Fisher scientific company, USA) in 1000 ml with 
acidified water of pH 6.0. The stock solution was standardized with sodium oxalate (S-
356 Lot 792406 Fisher scientific company, USA). This solution was used through all the 
experimental processes. 
 
2.5.2   Method and Procedure 
 
 
The full text of the computer program used for the calibration of SIA system can be found 
in the appendice I (page 163); the full components of the SIA manifold are diagramed in 
fig. 13. The following steps were the protocol applied for the calibration: 
 
I. Water was linked to the SP through the in-position mode to push reagents to the 
required part of the SI analyzer manifold. 
II. KMnO4 Standard solutions were linked to the MPV through ports 2, 3, 4, 5, and 6 
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III. The syringe was filled with 5000 µl of water by directing the two-way valve to the in-
position mode with flow rate of 100µl/s 
IV. Tubes were loaded with their respective solutions by performing aspiration runs and 
directing the two-way valve to the out-position mode with flow rate of 150µl/s 
V. With a different flow rate, the syringe was dispensed 900 µl.   
VI. The appropriate volume of potassium standard solutions was aspirated with flow rate 
of 150µl/s into the HC 
VII. The appropriate volume of product will be dispensed at the required flow rate to the 
Z and, simultaneously, the reference and absorbance scan will be carried out. Maximum 
value of the monitor peak will record as the value of the absorbance of the appropriate 
standard solution. 
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Figure 13: SIA manifold comprised of; A. carrier (water); SP. 5 mL syringe pump; HC.         
Holding coil; V. eight ports selector valve; RC. Reaction coil; (std1, std2, std3, std4, and 
std5) = KMnO4 standard solutions; RC. Reaction coil; D. spectrophotometer; PC Computer 
and W. waste 
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2.5.3   Calibration Curve 
 
 
A calibration plot was constructed by running the system at a fixed wavelength of 527 nm 
using different concentrations of potassium permanganate in the range of 50 to 250 mg l-
1. A typical SIA-Gram of absorbance versus concentration is shown in Fig. 14. It is clear 
that prominent well-defined five peaks are produced with a clear increase in the 
absorbance maxima; the sixth peak appears for the permanganate solution labeled as an 
unknown. The absorbances obtained in Fig. 14 were plotted versus the corresponding 
concentration were linear (Fig. 15) with the following calibration equation: A = 0.0590 + 
0.0109 x C; with R2 = 0.9985 indicating excellent linearity with a standard deviation of 
less than 1.0, emphasizing excellent precision. 
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 Figure 14 Typical SIA-Gram of Absorbance versus time for different standard 
concentrations of potassium permanganate as std-1=50 mg l-1; std-2 = 100 mg l-1; std-3 = 
150; std-4=   200 mg l-1; std-5 = 250 mg l-1; and an unknown claimed as 150 mg l-1.  
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Figure15 Calibration curve utilizing different standard concentrations of potassium 
permanganate between 50 mg l-1 to 250 mg l-1
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2.6   DETERMINATION OF KETOCONAZOLE 
 
 
 
2.6.1   Preparation of Reagent and Standard Sample Solutions 
 
1. Ketoconazole tablets: 20 tablets from the proprietary drugs were accurately weighed, 
crushed and powdered. The amount of the powder containing the appropriate weight to 
give 1000 ppm Ketoconazole was dissolved in about 40 ml of acidified water; heated for 
three minutes filtered and then it was made up to 100 ml volume in a 100 ml volumetric 
flask after cooling. Further dilutions could be made from the same. 
2. Sulfuric acid Solution (0.01 mol dm-3) A stock solution of 0.01 mol dm-3 H2SO4 (95-
98% Specific gravity 1.84 kg / l, Merck, UK) was prepared the usual way. Working 
solutions were prepared by dilutions.  
3. Cerium (IV) (500 ppm) A stock solution was prepared by dissolving exactly about 
0.25 g of dried cerium(IV) ammonium sulfate [Ce(NH4)4SO4.XH2O] (Fluka AG, CH-
9470 Buchs, Switzerland) in 10 mL of 0.5 mol L-1 sulfuric acid and diluting to 500 ml  
with distilled water in a calibrated flask. 
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2.6.2   Method and Procedure  
 
 
 
The full text of the computer program used for the determination of ketoconazole can be 
found in the appendice II (page 171): the full components of the SIA manifold are 
diagramed in fig. 16. The following steps were the protocol applied for the calibration: 
 
I. Water was linked to the SP through the in-position mode to push reagents to the 
required part of the SI analyzer manifold. 
II. Cerium (IV) (R) was linked to the selector valve through port 2; Ketoconazole 
standard solutions prepared in the range 5 to 240 ppm were linked to the selector valve 
through ports 3, 4, 5, 6, and 7 while the unknown concentration of KC which is usually 
the tablet solution was linked to the selector valve through port 8. Tubings were loaded 
with their respective reagents by an aspiration run. 
III. The syringe was filled with 5000 µl of water by directing the two-way valve to the in-
position mode with flow rate of 100µl/s 
IV. Tubes were loaded with their respective solutions by performing aspiration runs and 
directing the two-way valve to the out-position mode with flow rate of 100µl/s 
V. With a different flow rate, the syringe was dispensed 2000 µl.   
VI. The appropriate volume of Cerium (IV) standard solutions was aspirated with flow 
rate of 100µl/s into the HC 
VII. The appropriate volume of product will be dispensed at the required flow rate to the 
Z and, simultaneously, the reference and absorbance scan will be carried out. Maximum 
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value of the monitor peak will record as the value of the absorbance of the appropriate 
standard solution.  
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Figure 16: SIA manifold comprised of; A. carrier (water); SP. 5 mL syringe pump; HC. 
Holding coil; V. eight ports selector valve; RC. Reaction coil ; R Ce (IV); KC 
Ketoconazole solutions; RC. Reaction coil; D Spectrophotometer; PC Computer and W. waste 
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2.7   DETERMINATION OF DICLOFENAC SODIUM 
 
 
 
2.7.1   Preparation of Reagent and Standard Sample Solutions 
 
1. Diclofenac sodium tablets: 20 tablets from the proprietary drugs were accurately 
weighed, crushed and powdered. The amount of the powder containing the appropriate 
weight to give 150 ppm Diclofenac sodium was dissolved in about 40 ml of acidified 
water; heated for 3 minutes then it was made up to volume in a 100 ml volumetric flask 
after cooling. Further dilutions could be made from the same. 
2. Potassium permanganate (0.0199 mol dm-3): A standard solution was prepared by 
dissolving exactly about 3.5 g of dried potassium permanganate (P-279 Lot 746030 
Fisher scientific company, USA) in 1000 ml with acidified water of pH 6.0. The stock 
solution was standardized with sodium oxalate (S-356 Lot 792406 Fisher scientific 
company, USA). This solution was used through all the experimental processes. 
3. Sulfuric acid Solution (6.0 x 10-6  mol dm-3). A stock solution of 6.0 x 10-6 mol dm-3 
H2SO4 (95-98% Specific gravity 1.84 kg / l, Merck, UK) was prepared the usual way. 
Working solutions were prepared by dilutions. 
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2.7.2   Method and Procedure  
 
 
The full text of the computer program used for the determination of Diclofenac sodium 
(DCS) can be found in the appendice III (page 180): the full components of the SIA 
manifold are diagramed in fig. 17. The following steps were the protocol applied for the 
calibration: 
 
I. Potassium permanganate (R) was linked to the selector valve through port 2, Diclofenac 
sodium (DCS) standard solutions prepared in the range 20 to 250 ppm were linked to the 
selector valve through ports 3, 4, 5, 6, and 7 while the unknown concentration of DCS 
which is usually the tablet solution was linked to the selector valve through port 8. 
Tubings were loaded with their respective reagents by an aspiration run. 
II. The syringe pump was filled with acidified water as a carrier (C) by directing the two 
way valve to the (in-position) mode. 
III. 1500 µl acidified water carrier solution were dispensed to wash the holding coil (HC), 
Reaction coil (RC), the Z photo cell and to adjust the absorbance of the 
spectrophotometer to zero. 
IV. With a 100 µl/s flow rate, 50µl potassium permanganate, and 50 µl of the drug were 
sequentially aspirated into the holding coil. 
V. A short reverse stroke was performed to allow all reagents to mix with a flow rate of 100 
µl/s followed by continuous dispensing towards the detector with flow rate of 10 µl/s (D) 
for 30 seconds and hence the absorbance (A) was recorded. 
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VI. The steps 2 to 5 were repeated but aspirating the drug sample from the other selector 
valve ports. 
VII. The unknown concentration of the DCS solution was directly recorded from the analysis 
page in the FIALab software. 
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Figure 17: SIA manifold comprised of; A. carrier (water); SP. 5 mL syringe pump; HC. 
Holding coil; V. eight ports valve; RC. Reaction coil; R. KMnO4; DCS Diclofenac 
sodium solutions; RC. Reaction coil; D spectrophotometer; PC Computer and W. waste
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 CHAPTER 3 
 
SEQUENTIAL ININJECTION ANALYSIS SPECTROPHOTOMETRIC 
METHOD FOR THE ASSAY OF KETOCONAZOLE IN 
PHARMACEUTICAL PREPARATIONS 
 
3.1   KETOCONAZOLE (KC) LITERATURE REVIEW  
 
Ketoconazole (KTZ), cis-1-acetyl-4-[4-[[2-(2, 4-dichlorophenyl)-2-(1H-imidazole 
1ylmethyl)-1,3-dioxolan-4-yl] methoxy] phenyl] piperazine (Scheme 2) is a highly 
effective broad spectrum antifungal agent. It is used to treat a wide variety of superficial 
and systemic mycoses and has the advantage over other imidazole` derivatives of 
producing adequate sustained blood levels following oral administration [48]. KTZ has 
been evaluated against Trypanosoma cruzi, the causative agent of Chagas disease, and it 
was found to be very effective than other types of drugs [49-52]. Chagas disease an illness 
which currently afflicts over 17 million people in Latin America and ranks as the third 
largest parasitic disease worldwide after malaria and schistosomiasis [53]. Recently, new 
drugs of KTZ that is coordinated to transition metals, such as Ru, Rh, Cu, Au, and Pt, 
result in a remarkable enhancement of the biological activity as anti Trypanosoma cruzi   
[54, 55]. The characterization of these complexes was achieved through NMR, EPR, IR, 
UV-vis, elemental analysis, and also an X-ray diffraction study. The biological activities of 
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 these complexes against the epimastigote form of Trypanosomes cruzi were also evaluated 
indicating that all of them inhibit the proliferation of the parasite [56]. Some methods have 
been reported for its determination including: 
Potentiometry: It is the official methods according to British and US pharmacopoeia 
monographs the method is based on the potentiometeric titration of the drug solution in 
anhydrous acetic acid with 0.1 M Perchloric acid and detection of the equivalence point 
potentiometrically [57-58].    
Spectrophotometry: Khalil Farhadi and Ramin Maleki proposed a new spectrophotometric 
method for the determination of ketoconazole in pharmaceutical preparations the method is 
based on the coupled redox-complexation reactions, which proceed in the ketoconazole-
iron (III) and 1, 10-phenanthroline systems and monitoring of the colored complex at 512 
nm. [59].  
P.Y. Khashaba et al suggested Simple spectrophotometric and spectrofluorimetric methods 
for the determination of antifungal drugs; (clotrimazole, econazole nitrate, Ketoconazole, 
miconazole and tolnaftate). Spectrophotometric one depends on the interaction between 
imidazole antifungal drugs as n-electron donor with the p acceptor 2, 3-dichloro-5, 6-
dicyano- 1, 4-benzoquinone (DDQ) in methanol or with p-chloranilic acid (p-CA) in 
acetonitrile [60]. 
Abdel-Gawad F. M, established that ketoconazole reacts with iron (III) chloride in the 
presence of potassium thiocyanate to form a pink complex (2:1) that is soluble in 1, 2-
dichloroethane with a maximum absorbance at 510 nm. [61]. 
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 Mirjana P. Vojec, et al studied the acid-base equilibria of a diprotic, slightly hydrosoluble 
base ketoconazole in homogeneous and heterogeneous water systems. The determinations 
were performed at 25 ºC at a constant ionic strength of 0.1M (NaCl). The acidity constant 
Ka1 was determined by potentiometric (Pka1 3.20) and spectrophotometric (pKa1 3.26) 
methods. A pKa2 constant of 6.10 was obtained based on the equilibrium constants pK s0 
4.84 and pK s1 –1.26, determined in a heterogeneous ketoconazole system. The obtained 
values of the constants served to calculate the solubility and the distribution of the 
equilibrium forms of ketoconazole as a function of pH. On the basis of the distribution of 
the equilibrium forms of ketoconazole, a spectrophotometric method for the determination 
of its content in commercial tablets was developed. The determinations were performed at 
225 nm in 0.1 M HCl. The method is simple and rapid and enables the direct 
spectrophotometric determination of the content of ketoconazole without previous 
isolation. [62]. 
F. Jalali & A. Afshoon presented a sensitive spectrofluorimetric method for the detection 
of ketoconazole, based on formation of a complex between ketoconazole and β-
cyclodextrin, the formation of this complex was followed by spectrofluorimety. The 
inclusion of ketoconazole in β-cyclodextrin cavity enhanced the native fluorescence of the 
drug. [63]. 
Erika Rosa Maria Kedor-Hackmann et al developed a spectrophotometric method for 
quantitative determination of ketoconazole in commercial and simulated emulsion 
formulations, the method is based on quantitative first-derivative UV spectrophotometric 
determinations using the zero-crossing method at 257 nm, with methanol as background 
solvent. [64]. 
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 F. Jalali et al described spectrofluorimetric determination of Ketoconazole in 
Cetyltrimethyl-ammonium Bromide medium; the method was successfully applied to the 
determination of low concentrations of ketoconazole in pharmaceutical preparations and 
blood serum sample. [65]. 
Complexation; F.M. Abou-Attia et al developed a spectrophotometric method for the 
determination of three pharmaceutical piperazine derivatives, namely ketoconazole (KC), 
trimetazidine hydrochloride (TMH) and piribedil (PD). This method is based on the 
formation of yellow orange complexes between iron (III) chloride and the investigated 
drugs. [66]. 
El-Ragehy Nairman A. and El-Saharty Yasser S., Investigated ketoconazole copper(II) and 
cobalt(II) complexes and their spectrophotometric applications, Ketoconazole, as a ligand, 
reacts quantitatively with copper(II) and cobalt(II) to form blue-colored, stable complexes 
in dichloromethane. These complexes can be spectrophotometrically measured at 720 and 
612.5 nm in the case of Cu (II) or Co (II), respectively. [67] 
Chromatography; Adela Arranz et al described Capillary zone electrophoresis (CZE) 
method for simultaneous determination of a mixture of three imidazolic antifungal drugs. 
[68]  
E.M. Abdel-Moety et al developed High-performance liquid chromatographic technique 
for the determination or some azolcsantifungals namely, clotrimazole (CZ), ketoconazole 
(KZ) and fluconazole (FZ), in pure forms and in pharmaceutical formulations. [69] 
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Scheme 2: Ketoconazole drug 
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 3.2   RESULTS AND DISCUSSION 
3.2.1   Reaction Mechanism 
The present system is based on the oxidation of the Ketoconazole with cerium (IV) in 
sulfuric acid media and monitoring the oxidized coloured form of the drug 
spectrophotometrically utilizing the sequential injection analysis technique. The oxidized 
form of the drug was found to be stable for more than two minutes and identified as a 
mono-radical species the absorbs at the wavelength of maximum absorbance at 492 nm.  
A recent study on the electro-oxidation of KCZ in aqueous and non-aqueous media proved 
that the KCZ is initially oxidized reversibly with the loss of one electron to the cation 
radical (KC·+). This radical can be stabilized by resonance, resulting in the observed pink-
red color product. The stability of the cation radical is completely dependent on the 
conditions of solution, so that it gradually decays via a chemical reaction in polar solvent 
and/or in weak acidic aqueous media. Also, it was found that, KC·+ can be further oxidized 
with the loss of the second electron to give some stable products [59]. 
 On basis of the results mentioned above, the chemical oxidation of KCZ was investigated 
with cerium(IV) as an oxidant in sulfuric acid media. The newly developed 
spectrophotometric method utilizes the SIA as the major technique for solution handling 
graphically represented as in Scheme 3 
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KC + Ce (IV)                                  KC+ + Ce (III) 
 
 
 
Ketoconazole (KC) +   Cerium  (IV)                               (KC) radical + Cerium (III) 
 
          |                                |                                                                  |                     |                                      
 
(Colorless)                 (Yellow color)                                    (Pink color)  (Colorless)                                 
 
                                    
 
Scheme 3:  Reaction scheme for the proposed SIA method for the determination of 
Ketoconazole 
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 3.2.2   Method optimization 
A preliminary investigation was conducted to find out the experimentally possible range of 
the levels of variables presumed to be potentially affecting on the efficiency of the SIA 
method, namely flow rate, sulfuric acid concentration and cerium (IV) concentration. 
Three chemometrics approach were applied for the purpose of SIA system optimization, 
namely univariate, factorial design and multisimplex. 
 
3.2.2.1   Uni-variate Method Approach 
The method for the determination of Ketoconazole by Sequential injection was optimized 
using the uni-variate method approach The univariant, one-variable-at-a-time, method 
optimizes one variable using different levels of that variable and fixed levels of other 
variables in a system [70]. In this concern, a number of experiments were conducted using 
sulphuric acid (0.35, 0.4, 0.45, 0.5, 0.55, and 0.6 mol/l), cerium (IV) (50, 100, 150, 200, 
300, 450, and 600 ppm), and different flow rates ranging from 10 to 50 µl/s.  
 
3.2.2.1.1   Delay time  
Delay time ensures more intensely colored products formation; this subsequently enhances 
the sensitivity of the method but on the other hand the colored products may not be so 
stable and decomposition of the colored product may take place before monitoring of the 
absorbance and this will affect the sensitivity of the method. In case of Ketoconazole the 
delay time was varied between 30 to 180 seconds and it was found that the pink 
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 Ketoconazole radical is stable up to 120 second without any significant decrease in the 
absorbance. (Table 4 and figure 18) 
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             Table 4 The effect of delay time on the absorbance of Ketoconazole radical 
     EXP. NO. DELAY TIME (S) ABSORBANCE* 
1 30 0.333 
2 90 0.338 
3 120 0.327 
4 150 0.298 
                      *Average of three determinations 
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Figure 18 The effect of the delay time on the absorbance peak height of 50 ppm KC 
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 3.2.2.1.2   Flow rate 
 
The effect of the flow rate on the peak absorbance was investigated and found to be a 
major affecting parameter on the absorbance. Low flow rate ensures that the colored 
products spend more time in the flow cell and absorbance is well measured, it also 
provides more time for the colored complex to be formed in route to the detector. The 
optimum flow rate for the proposed SIA method was observed to be 30 µL/s. There was a 
drop in absorbance at higher flow rate because of the high speed of the colored KCZ 
radical produced through the flow cell and hence very low sensitivity (table5 and 
figure19). 
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              Table 5 The effect of flow rate on the absorbance of Ketoconazole radical 
     EXP. NO. FLOW RATE 
ΜL/S 
ABSORBANCE* 
1 10 0.221 
2 20 0.291 
3 30 0.456 
4 40 0.338 
5 50 0.159 
                       *Average of three determinations 
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Figure 19 The effect of the flow rate on the absorbance peak height of 50 ppm KC 
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 3.2.2.1.3   Sulfuric acid concentration  
 
The concentration of sulfuric acid is one of the significant parameters affecting the 
absorbance of the product, since the oxidation power of Ce (IV) depends on the acidity of 
the medium. Long series of sulfuric acid concentrations were prepared for the purpose of 
studying the effect of the acid concentration on KC radical absorbance. The optimum acid 
concentration was found to be 0.55mol/l (table 6 and figure 20)  
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              Table 6 Effect of the acid concentration on the absorbance of KC radical  
     EXP. NO. ACID M ABSORBANCE* 
1 0.35 0.313 
2 0.40 0.315 
3 0.45 0.314 
4 0.50 0.338 
5 0.55 0.350 
6 0.60 0.304 
                        *Average of three determinations 
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Figure 20 The effect of the acid on the absorbance peak height of 50 ppm KC 
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 3.2.2.1.4   Cerium (IV) concentration  
 
Cerium (IV) is a powerful and strong oxidizing agent. It is important to optimize the 
concentration of cerium(IV) in case of Ketoconazole, it was found that the color of the 
chemically produced cation radical immediately disappeared in the presence of excess 
Ce(IV), probably due to further oxidation of KC+ to colorless dication (KC2+) (table7 and 
fig. 21.[59] 
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       Table 7 The effect of the Ce (IV) concentration on the absorbance of KC radical 
     EXP. NO. CERIUM PPM ABSORBANCE* 
1 50 0.276 
2 100 0.331 
3 150 0.352 
4 300 0.350 
5 450 0.270 
6 600 0.242 
                       *Average of three determinations 
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Figure 21 the effect of Ce (IV) concentration on the absorbance peak height of 50 ppm   
KC 
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 3.2.2.2   Factorial Design 
In this work, three level factorial designs were applied to the three variables. The highest, 
encoded as (+1), and the lowest, encoded as (−1), levels of the factorial design were 
obtained from the preliminary investigation using univariant approach, while the medium 
level, encoded as (0), was mathematically calculated. A total of twenty-seven experiments, 
as a result of 33 full factorial designs, were conducted. Table 8 presents the adopted matrix 
and the experimental results. By the means of SigmaPlot® software, the results obtained for 
the response versus each two variables were interpolated and graphed (Figs. 22, 23 and 
24). Fig. 22 reveals that the response significantly increases as cerium (IV) concentration 
and flow rate increases this indicating that cerium (IV) concentration and flow rate 
significantly affects the response and the maximum absorbance is obtained at the medium 
values of Ce (IV) as well as flow rate, and this point is clear explained with the contour 
plot Fig. 25.  Fig. 23, shows that at the two ends of the Ce(IV) concentration the response 
is decreased to its lowest values and this observation can be explained as follow: at the 
lower value there were no sufficient amount of Ce(IV) and not all of the drug amount was 
oxidized and at high of Ce(IV) value the further oxidation of KC+  to the colorless KC++   
takes place. The highest response is obtained at medium values of Ce(IV) and the acid. 
Fig. 24 shows that the effect of acid concentration on the response is lower than the effect 
of flow rate and the response is significantly increases with the flow rate and reaches the 
highest at the medium value of the flow rate. 
Figure 25 contour plots of the data (cerium and flow rate) where the contour different 
colored zones show the response different values. The pink zone indicates the largest 
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 response value and it will be achieved if the levels of cerium(IV) and flow rate are both set 
at medium levels. There is no curve in the contour lines indicating the absence of the 
interaction between cerium and flow rate. Fig 26 and 27 the presence of non linear contour 
lines shows strong interaction between cerium and the acid (fig26) and also between the 
acid and flow rate (fig 27). 
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                  Table 8 A 33 factorial design matrix with experimental results (responses) 
Factors Experiment 
No. [CeIV] [Acid] F.r.µ / s 
*Response 
 
1 -1 -1 -1 0.150 
2 -1 -1 0 0.212 
3 -1 -1 +1 0.187 
4 -1 0 -1 0.164 
5 -1 0 0 0.260 
6 -1 0 +1 0.230 
7 -1 +1 -1 0.186 
8 -1 +1 0 0.257 
9 -1 +1 +1 0.133 
10 0 -1 -1 0.188 
11 0 -1 0 0.300 
12 0 -1 +1 0.289 
13 0 0 -1 0.183 
14 0 0 0 0.288 
15 0 0 +1 0.233 
16 0 +1 -1 0.197 
17 0 +1 0 0.340 
18 0 +1 +1 0.239 
19 +1 -1 -1 0.071 
20 +1 -1 0 0.169 
21 +1 -1 +1 0.166 
22 +1 0 -1 0.078 
23 +1 0 0 0.213 
24 +1 0 +1 0.233 
25 +1 +1 -1 0.096 
26 +1 +1 0 0.246 
27 +1 +1 +1 0.248 
                     *Average of three determinations 
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Figure 22 Surface plot of the response versus Ce (IV) concentration (ppm) and flow rate 
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Figure 23 Surface plot of the response versus sulphuric acid concentration (mol/l) And 
Ce(IV) concentration (ppm) 
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Figure 24 Surface plot of the response versus sulphuric acid concentration (mol/l) and 
flow rate µl/s 
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Figure 25 Contour Plot of Response vs. Flow rate, Ce(IV) 
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Figure 26 Contour Plots of Response vs.  Ce(IV), acid 
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Figure 27 Contour Plots of Response vs.  Acid, flow rate 
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 The ANOVA principle provides the basis of the statistical analysis aspect of factorial 
design by providing the mathematics for test statistic construction and derivation based on 
response model specification and the underpinning statistical theory [71]. 
Results obtained by using Minitab, Table 9 shows the ANOVA table produced by Minitab 
software. The p values for Cerium(IV) concentration, sulfuric acid concentration, and flow 
rate are zero. That means all factors are significant. In other words, cerium(IV), sulfuric 
acid, and flow rate are significantly affecting the response. Also the p values for two factor 
interaction and three factor interaction are smaller than 0.05 ( α). That means the 
interaction have a significant effect on the response.  
The interaction between the factors can be visualized with an interaction plot, Figures (28, 
29, and 30). The interaction plot graphs the means of the replicates, organized based on the 
three levels of the factors. The presence of non-parallel lines in the interaction plot is 
indicative of the occurrence of an interaction effect and that the interaction is reflecting a 
non-uniform order of response. [71].  
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Table 9: ANOVA table by using Minitab  
 
 
Analysis of Variance for Response 
 
Source                    DF         SS         MS       F      P 
[CeIV]                     2   0.230650   0.115325   73.22  0.000 
[Acid]                     2   0.076386   0.038193   24.25  0.000 
Flowrate                   2   0.688518   0.344259  218.56  0.000 
[CeIV]*[Acid]              4   0.048150   0.012037    7.64  0.000 
[CeIV]*Flowrate            4   0.044475   0.011119    7.06  0.001 
[Acid]*Flowrate            4   0.039075   0.009769    6.20  0.001 
[CeIV]*[Acid]*Flowrate     8   0.044334   0.005542    3.52  0.007 
Error                     27   0.042528   0.001575 
Total                     53   1.214116  
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Figure 28: Interaction plot for cerium and the acid showing that the two factors influence 
each other (non- parallel lines). 
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Figure 29: Interaction plot for cerium and the flow rate showing that the two factors 
influence each other (non- parallel lines) 
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Figure 30: Interaction plot for acid and the flow rate showing that the two factors 
influence each other (non- parallel lines). 
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 Another ANOVA approach was applied utilizing Minitab software to investigate the main 
factor effect i.e. the effect factor (Ef) on the response. It is calculated using equation 1. 
Therefore, a 23 factorial design was adopted to calculate the effect factors as in table 10. 
The interaction effect factor explains the level of the interaction effect between variables 
on the response of a system. The main and interaction effect factors were calculated and 
the results obtained are introduced in table 11 [71]. The main effect factors disclose that 
the cerium(IV) slightly and negatively affects the response while acid concentration and 
flow rate significantly and positively affect the response. The two-variable interaction 
effect factor between acid concentration and flow rate is higher than that between flow rate 
and the   cerium(IV) concentration or acid concentration and Ce(IV) concentration and so 
for the three variable interactions.  
Effect of each factor = (effect contrast) / ( 2k-1)                                           (1) 
Whereas (effect contrast) can be calculated using table 12, (k) is number of factors 
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                   Table 10: 23 factorial design matrix 
Combination Ce(IV) Acid Flow rate *Response 
(1) - - - 0.150 
a + - - 0.071 
b - + - 0.186 
ab + + - 0.096 
c - - + 0.187 
ac + - + 0.166 
bc - + + 0.133 
abc + + + 0.248 
                              *Response denotes a triplicate response measurement 
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            Table 11 The effect of variables on response 
Effect  Variable Value 
Ce(IV) -0.019 
Acid 0.022 
Main 
Flow rate 0.058 
Ce(IV)* Acid 0.031 
Ce(IV)* Flow rate 0.066 
Tow-variable interaction 
Acid* Flow rate -0.008 
Three-variable interaction Ce(IV)* Acid* Flow rate 0.0037 
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                Table 12 Contrast for a three factor two-level experiment 
Effects Contrast 
A a + ab + ac + abc – (1) – b – c – bc 
B b + ab + bc + abc – (1) – a – c – ac 
AB (1) + ab + c + abc – a – b – ac – bc 
C c + ac + bc + abc – (1) – a – b – ab 
AC (1) + b + ac +abc – a – ab – c – bc 
BC (1) + a + bc + abc – b – ab – c – ac 
ABC a + b + c + abc – (1) – ab – ac – bc 
                  A, B and C denotes the factors 
 
 
 
 
 
 
 
 
3.2.2.3   MultiSimplex method 
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 The Multisimplex® software package was employed to find out the optimum levels of 
variables potentially interact, i.e. the acid concentration cerium(IV) concentration, and 
flow rate. Reference values and steps as the initial inputs of the simplex method are 
introduced in Table 13. Although Multisimplex® is not restricted by boundaries, some 
levels are impossible to be conducted practically. Hence, the same ranges of levels of 
parameters obtained from the preliminary investigation were considered in the 
Multisimplex®. Up to 20 sequential experiments were practically carried out (table 14) and 
the response function progress is plotted in Fig. 31. The advantage of the Multisimplex® 
method over the other simplex methods, i.e. basic simplex, modified simplex and super 
modified simplex, is that the optimum levels are obtained in less number of trials [72]. The 
first four trials are proposed based on pure mathematical calculation while the other 
consequent trials are proposed based on both mathematical calculations and the inputs of 
the response of a previous experiment. As depicted in Fig. 21, the response starts with low 
values and sharply increases at experiment 4 and obtains the maximum at experiment 17, it 
can be concluded that 0.44 mol/l sulphuric acid, 4.4×10-4 mol/l cerium (IV) and flow rate 
16.202 µl/s are the optimum experimental conditions of the adopted SIA method. 
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 Table 13 Initial inputs of the Multisimplex® (concentration in mol L-1) 
MultiSimplex inputs                      Acid                       Ce(IV)                      Flow rate µl/s 
Reference value                              0.3                            4.8×10-4                                        15                 
Step                                                0.03                          4×10-5                                               2              
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Figure 31 Response function progress of the Multisimplex® optimization 
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 Table 7 Concentration values (mmol in 50 mL solution), flow rate and corresponding 
absorbance 
Trial 
number 
Acid 
(mmol) 
Ce(IV) 
(mmol) 
Flow rate  
(µl/s) 
*Absorbance 
1 14.25 0.025 14 0.189741 
2 15.75 0.023 14 0.208673 
3 14.25 0.023 16 0.230702 
4 15.75 0.025 16 0.237138 
5 16.25 0.022 16.667 0.2724501 
6 17.25 0.021 18 0.2791007 
7 15.75 0.023 19.333 0.2494605 
8 18.25 0.023 19.555 0.2649777 
9 18.417 0.02 21.925 0.2498381 
10 20.195 0.02 20.32 0.25874 
11 18.713 0.023 16.658 0.2990745 
12 18.861 0.024 14.025 0.202994 
13 15.947 0.025 15.822 0.2310246 
**6RE1 17.25 0.021 18 0.2511369 
14 19.133 0.021 19.196 0.2685093 
15 18.481 0.02 16.348 0.2839883 
16 20.301 0.022 16.801 0.3041627 
17 21.827 0.022 16.202 0.3113217 
18 20.214 0.022 13.609 0.217985 
19 19.403 0.021 17.799 0.2944458 
20 21.481 0.024 17.425 0.3027305 
                *Absorbance reading an average of 3 determinations 
                 **6RE1= Experiment 6 was reevaluated  
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 3.2.3   Method validation 
 
3.2.3.1   Linearity & range 
 A long series of standard solutions of Ketoconazole were subjected to the optimized SIA 
method for the purpose of calibration. Beer’s law was found to be obeyed in the 
concentration range of 30–180 µg/mL with weighed regression Abs. (a.u.) = 0.05286 + 
0.002687 KC µg/mL the correlation coefficient was 0.9965 indicating good linearity. 
Figure 32 and 33 shows a typical SIA calibration obtained under the optimum conditions 
for five consequent injection of five standard solutions of Ketoconazole (30, 60, 90, 120, 
150, and 180 µg/mL). Fig. 34 shows the SIAgram obtained under optimal conditions for 
five standard solutions of Ketoconazole pure samples followed with unknown solution of 
the same drug in tablet formulation. 
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Figure 32: The Absorbance of Ketoconazole radical versus drug concentration calibration 
plot  
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Figure 34 The SIA output obtained with proposed system, providing a Ketoconazole 
calibration plot between 30–180 µg/ml (std = standard), the peak for tablet unknown 
solution is shown. 
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 3.2.3.2   The accuracy 
The accuracy was examined by analyzing tablets formulations. The obtained results were 
realized by the US Pharmacopoeia (USP) method. USP provided a classical potentiometric 
titration method by Perchloric acid for Ketoconazole assay in tablets formulation. Analysis 
for the tablet sample was repeated three times, and the relative standard deviation (RSD) 
was calculated. The t-test values were also calculated. The results obtained are introduced 
in table 15. The obtained results indicating that the provided SIA method is accurate and 
repeatable as the t-test calculated were always less than the tabulated values at 95% 
confidence level.  
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Table 15 Results obtained by the SIA and US Pharmacopoeia methods for the analysis of 
Ketoconazole in tablets sample 
Drug Supplier 
 
Contents 
(mg) 
Samples Mean recovery ±RSD (%)a 
___________________________________
SIA method  USPc method 
tb-test value 
 
Nizoral 
 
 
Janssen 
Pharmaceutica 
N. V., 
Turnhoutseweg  
30, B-2340 
Beerse, 
Belgium 
 
Ketoconazole 
200 mg per 
tablet 
 
Ketoconazole 40 mg/l 
 
Ketoconazole 80 mg/l 
 
Ketoconazole120 mg/l 
 
99 ± 1.6          99.8  ± 1.3 
 
99.8 ± 1.6       99.5  ± 1.3 
 
99.8 ± 1.4       100  ± 1.0 
 
1.1 ( t Critical = 2.13) 
 
0.6 ( t Critical = 2.13) 
 
0.2 ( t Critical = 2.13) 
a Relative standard deviation for 5 replicates. 
b Student t-test values. 
c United State Pharmacopoeia. 
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 3.2.3.3   The intermediate precision 
 
The intermediate precision of the SIA method was examined by analyzing the same 
solutions 5 times over a week. Relative standard deviation (RSD) of the mean recovery for 
samples under study was 2.1 % indicating good intermediate precision.  
 
3.2.3.4   The limits of detection (LOD) and quantification (LOQ) 
The limits of detection (LOD) and quantification (LOQ) were also examined. LOD was 
calculated as 3.3(s/S) and LOQ as 10(s/S) where s is the standard deviation for five 
replicates of the measurement of placebo solution, S is slope of the weighed regression of 
calibration equation. The LOD and LOQ obtained were 0.77 and 2.3 µg/mL, respectively, 
indicating good detectability. [73]. 
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CHAPTER 4 
 
SEQUENTIAL ININJECTION ANALYSIS 
SPECTROPHOTOMETRIC METHOD FOR THE ASSAY OF 
DICLOFENAC SODIUM IN PHARMACEUTICAL PREPARATIONS 
4.1   DICLOFENAC (DCS) LITERATURE REVIEW 
 
Diclofenac, [o-[(2, 6-dichlorophenyl) amino] phenyl] acetic acid (Scheme 4) belongs to a 
class of nonsteroidal anti-inflammatory drugs (NSAIDs). In pharmacologic studies, 
diclofenac has shown anti-inflammatory, analgesic, and antipyretic activity. As with other 
NSAIDs, its mode of action is not know; its ability to inhibit prostaglandin synthesis, 
however, may be involved in its efficacy in relieving pain related to inflammation and 
primary dysmenorrheal. With regard to its analgesic effect, diclofenac is not a narcotic. 
Diclofenac is used in treating osteoarthritis, rheumatoid arthritis, and ankylosing 
spodylitis. Due to its low solubility [74] it is commercially available as its sodium salt. A 
number of analytical methods have been developed for the quantitative determination of 
this drug in dosage forms and in biological samples these methods includes:  
Spectrophotometry, J. A. Rodrigues and et al. described spectrophotometry methods 
utilizing SIA technique this methods based on the oxidation of Diclofenac with potassium 
permanganate in alkaline medium and the measurement of the green product formed [75]. 
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Snezana Mitic et al. described kinetic method for the determination of micro quantities of 
diclofenac sodium (DS) The method is based on a ligand-exchange reaction. The reaction 
was followed spectrophotometrically by monitoring the rate of appearance of the cobalt 
diclofenac complex at 376 nm [76].  
Marcelo M. Sena et al. proposed a simple and rapid analytical procedure for determination 
of diclofenac (DCF) in the presence of B vitamins, based on UV measurements [77] 
 Mahmoud Mohamed Issa et al. developed highly sensitive indirect atomic absorption 
spectrophotometric (AAS) methods for the determination of Diclofenac sodium and some 
other pharmaceutical. The method is based on the oxidation of the drugs with iron (III), 
the excess of iron (III) was extracted into diethyl ether and then the iron (II) in the 
aqueous layer was aspirated into an air-acetylene flame and determined by AAS. [78]. 
Agatonović-Kustrin S  et al. developed a new spectrophotometric method in which 
diclofenac sodium is analyzed and determined as its Fe (III) complex. The method is 
based on the reaction of Diclofenac sodium with Fe (III) chloride, in the presence of 
ammonium thiocyanate, in the pH range 4.2-6.5, forming a red chloroform extractable 
(2:1) complex with maximum absorbance at 481 nm. [79]. 
Souza, et al. proposed a modified procedure for the visible spectrophotometric 
determination of diclofenac, in pharmaceutical preparations using as reagent an aqueous 
solution of copper (II) the method is based on the monitoring of the green color complex 
which formed between copper(II) and diclofenac with a maximum light absorption at 680 
nm [80]. 
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Fluorometry methods were described by: Marcela A. et al. developed a 
spectrofluorometric method for the microdetermination of diclofenac sodium. The method 
is based on its reaction with cerium (IV) in an acidic solution and measurement of the 
fluorescence of the Ce (III) ions produced. [81]. 
A.M. Pimenta, et al. described method for the determination of diclofenac sodium. The 
method is based on the concept of sequential injection analysis [82]. 
Carreira LA et al. developed a new method for the determination of Diclofenac sodium in 
bulk and in pharmaceutical preparations. The method is based on using of Eu3+ ions as the 
Fluorescent probe. The technique was built around the hypersensitive property of the 
transitions of the fluorescent probe ion, Eu3+, at 616 nm [83]. 
Arancibia JA et al.  Studied the complex formed between alpha-cyclodextrin (CD) and the 
anti-inflammatory drug diclofenac in aqueous solution and also on its potential analytical 
applications. It was corroborated that the fluorescence emission band of diclofenac is 
significantly intensified in the presence of alpha-CD [84] 
Chromatography: Brett J. et al. determined Diclofenac sodium and some other 
pharmaceutical in water by Isotope Dilution Liquid Chromatography/Tandem Mass 
Spectrometry, The method employs solid phase extraction (SPE) and liquid 
chromatography/tandem mass spectrometry (LC-MS/MS), using electrospray ionization 
(ESI) in both positive and negative modes. [85]. 
Anping Deng et al. described   residue Analysis of the Pharmaceutical Diclofenac in 
Different Water Types Using enzyme-linked immunosorbent assay (ELISA) and GC−MS. 
[86] 
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Potentiometric: British pharmacopoeia described potentiometric method for the 
determination of dicolofenac sodium in tablet formulation; the method is based on 
dissolving of 0.250 g of the tablet powder in 30 ml of anhydrous acetic acid, titration of 
this solution against 0.1 M perchloric acid and determining the end-point 
potentiometercally [87].   
Zholt Kormosh et al. described Potentiometric determination of diclofenac in 
pharmaceutical formulation by membrane electrode based on ion associate of diclofenac 
with base dye Safranine T Fig. 35 (b) an using this ion associate as an electrode active 
substance for membrane electrode. [88] 
Electrochemical sensors: Z. Kormosh et al. prepared a novel diclofenac ion-selective 
electrode. [89]  
Zholt Kormosh et al. developed a new diclofenac-selective electrode based on an ion 
associate of diclofenac with a basic dye BIK as a membrane carrier [90] 
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                Scheme 4: Diclofenac sodium  
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Figure 35 (a) Diclofenac sodium and (b) Safranine T 
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4.2   RESULTS AND DISCUSSION 
4.2.1   Reaction Mechanism 
The chemical system is based on the reaction of permanganate with diclofenc sodium in a 
slightly acidic medium of 6.0 x 10-6 mol l-1 sulfuric acid and monitoring the absorbance 
peaks produced at 450 nm for the oxidized form of the drug utilizing the SIA technique.  
The chemical system is based on the reaction of permanganate with diclofenc sodium in a 
slightly acidic medium of 6.0 x 10-6 mol l-1 sulfuric acid and monitoring the absorbance 
peaks produced at 450 nm for the oxidized form of the drug utilizing the SIA technique.  
Permanganate appearing as four peaks due to the different oxidation forms of what?? as in 
plot 2. The UV absorption spectrum of the tetrahedral d0 complex MnO42- has become a 
prototype spectrum in transition-metal spectroscopy; a well-resolved experimental 
spectrum that has been published in 1967 by Holt and Ballhausen [91]. This prototype 
spectrum is attributed to the vibronic features of the absorption spectrum of permanganate 
that can be reproduced within this vibronic coupling scheme, including the vibrational 
structure due to Jahn-Teller active normal modes that lead to minima at distorted (lower 
symmetry) geometries [91-92]. The spectra illustrated in Fig. 36 clearly show that the 
reaction was found to be time dependent. The absorbance decreases while the absorbance 
maxima of the oxidized form of the drug increase by time as in the same figure (plots 3 to 
8) thus resulting in a well defined isosbestic point (Fig. 36).  
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Figure 36 Absorption spectra of various solutions (1 = blank; 2= a solution of pure 
potassium Permanganate, 3 to 8= spectra of a mixture of DCS and KMnO4   at 0s, 40s, 
80s, 120s, 160s, and 200s, respectively). i= shows the isosbestic point. 
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 However, the absorbance of DCS-oxidized form monitored at the wavelength of 450 nm 
was found to be reasonable and measurable after a delay time of 30 seconds. It is worth 
mentioning here that SIA technique is unique in measuring the absorbance values at a 
fixed time with extremely high precision in comparison with the traditional 
spectrophotometry.  
The Electron paramagnetic resonance (EPR) spectrum was scanned for the reaction 
products after completion (Fig. 37). The plot is showing very stable sixtet hyperfine 
splitting indicative of the well known EPR signal feature of manganese (II) [93]. 
Additionally very weak triplet of sixtet hyperfine splitting were also observed 
corresponding to the oxidized form of the drug system. Around g = 2.002, superimposed 
radical feature peak appeared, presumably due to the oxidized form of the drug as a 
diradical species. This diradical species was confirmed by performing another EPR scan 
for the drug with a milder cerium (IV) oxidant in acidic medium. This diradical species 
was found to too weak to be considered for any quantitative measurements.   
It is therefore all quantitative measurements and investigations were carried out by 
monitoring the absorbance of another oxidized species of the drug at 450 nm which is 
believed to be the quinone imide stable compound in acidic medium [75] that is shown by 
the mechanism illustrated in scheme 5  
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Figure 37 Electron Paramagnetic Resonance (EPR) spectrum for a mixture of Diclofenac   
sodium and potassium permanganate. 
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Scheme 5: Proposed reaction mechanism for the oxidation of Diclofenac sodium with   
potassium permanganate in acidic media 
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 4.2.2   Method optimization 
The results obtained by the present SIA method for the assay of DCS after oxidation with 
permanganate was found to be affected by the change in the permanganate concentration 
and the flow rate of aspiration and dispensing. The simple univariate type of optimization 
was utilized for this purpose as manifested below.  
4.2.2.1   Optimization of the permanganate concentration 
The univariant, one-variable-at-a-time, in this concern, a number of experiments were 
conducted using various potassium permanganate concentrations (50, 100, 150, 200, 250, 
350, 450, and 500 mg l-1) in acidic medium, keeping the acid concentration and the flow 
rate constants at 6 x 10-6 mol l-1 and 5 µl s-1, respectively. The absorbance of the brown 
color produced at 450 nm was found to increase by increasing potassium permanganate 
concentration (Fig.38 and Table 16). The optimum potassium permanganate concentration 
was considered to be 250 mgl-1 as the increase of the absorbance was not highly 
significant beyond this concentration. However, though the absorbance kept increasing 
with potassium permanganate concentration more than 250mgl-1, there is fear that the 
tubing of the SIA system would be affected. 
 
 
 
 
 135
  
 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
30 130 230 330 430 530
 [KMnO4]
A
bs
.
 
Figure 38 The effect of KMnO4 concentration on the absorbance (430 nm) of a solution 
of 30 mgl-1 DCS. Absorbance recorded was an average of three determinations 
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           Table 16: The Effect of KMnO4 concentration on the absorbance (430 nm) of  
           DCS 
 
Exp. No. KMnO4 (ppm) Absorbance* 
1 
2 
3 
4 
5 
6 
7 
8 
50 
100 
150 
200 
250 
350 
450 
500 
0.067 
0.095 
0.132 
0.181 
0.24 
0.27 
0.33 
0.35 
 
 
 
 
 
 
 
 
 
 
          *Average of three determinations 
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 4.2.2.2   Optimization of the Flow Rate 
Again, the univariant type of optimization was performed for determining the suitable 
flow rate for quantitative assay of the DCS. Series of experiments were conducted using 
different flow rates ranging between 5 and 25 µls-1, keeping the acid and permanganate 
concentrations constants at 6 x 10-6 M and 250mgl-1, respectively. The absorbance of the 
brown color produced at 450 nm was found to decrease by increasing the flow rate (Table 
17 and Fig. 39). The decrease in the absorbance became insignificant when the flow rate 
exceeded 15 µls-1. This observation is in quite agreement with the fact that the reaction is 
time dependent. The optimum flow rate for the proposed SIA method was considered to 
be 5 µls-1.  
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Figure 39 The effect of the flow rate on the absorbance (430 nm) of 30 mgl-1 DCS. 
Absorbance recorded was an average of three determinations. 
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  Table 17: The Effect of the flow rate on the absorbance of DCS 
Exp. No. Flow rate  (µl/s) Absorbance* 
1 
2 
3 
4 
5 
5 
10 
15 
20 
25 
 
0.341 
0.275 
0.262 
0.252 
0.232 
 
 
 
 
 
 
 
 
                       *Average of three determinations 
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 4.2.3   Analytical Appraisal  
Validation of the compendial procedure must meet proper standards of accuracy and 
reliability supported by sufficient data to document their validity. Diclofenac sodium raw 
material and in dosage form is determined by potentiometry in the BP 2007 [87]. The 
method is internally validated following the USP30-NF25 procedure. The following 
typical analytical performance characteristics are considered: linearity and range, limit of 
detection, limit of quantitation, accuracy, precision, specificity, and robustness. 
 
4.2.3.1   Linearity and Range 
The linearity of calibration curves obtained from the optimized SIA method set here has 
been tested over a range of 15 – 150 mg l-1 standard solutions of diclofenac sodium in the 
absence of the drug matrix (excepients) components. Beer’s law was found to be obeyed 
over a concentration range of 30–135 µg ml-1 with a regression equation of y = 0.0987 + 
0.00426 x and correlation coefficient of better than 0.998 Table 18 and Fig.40 show a 
typical SIA calibration obtained under the optimum conditions by triplicate consequent 
injection of the DCS standard solutions.  
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 Table 18 Diclofenac sodium calibration obtained from the optimized SIA method 
Concentration of Diclofenac 
mg/ml 
Absorbance Acceptance criteria 
15 
30 
45 
60 
75 
90 
105 
120 
135 
150 
0.180 
0.226 
0.282 
0.354 
0.427 
0.491 
0.540 
0.615 
0.666 
0.700 
 
Regression:   y  = ax + b 
a  = 0.00426 
b  = 0.0987 
r2  = 0.998 
0.998 – 1.002 
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Figure 40:  The Absorbance of the DCS at 450 nm versus concentration. 
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 4.2.3.2   The limits of detection (LOD) and limit of quantification (LOQ) 
The limits of detection (LOD) and limit of quantification (LOQ) were also examined. 
LOD was calculated as 3.3(s/S) and LOQ as 10(s/S) where s is the standard deviation for 
nine replicates of the measurement of the blank solution, S is slope of the weighed 
regression of calibration equation. The LOD and LOQ obtained were 0.24 and 0.7 µgml-1, 
respectively, indicating good detectability [73]. 
 
4.2.3.3   Accuracy   
The accuracy of an analytical procedure is usually established across the linearity range of 
the calibration curves. The validation is conducted chemometrically by comparing the 
results obtained from the new SIA method with those obtained from the standard BP 2007 
[87] method. In this respect, the same batches of samples containing diclofenac sodium in 
dosage forms were quantitatively analyzed for the active drug by both, the new SIA 
method and by the BP standard method. The percentage recovery, standard deviation and 
finally the t-test values were calculated. Thus, a minimum of 9 determinations over a 
minimum of 3 concentration levels covering a specified range (e.g. 3 concentrations/3 
replicates each of the total analytical procedure).  
The proposed SIA method was used to determine Diclofenc sodium in proprietary 
pharmaceutical formulations (tablet). Table 19 shows the results obtained. The SIA results 
obtained were statistically compared by the results obtained for the assay of the same 
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 samples of Diclofenc sodium in tablet formulations following the British Pharmacopoeia 
standard method [87]. 
For each sample type, the mean concentrations (n = 5) of Diclofenc sodium obtained with 
the two methods were compared using the student t-test to evaluate for the accuracy of the 
new SIA method as in Tables 19 and 20. The t-test values were always less than the 
tabulated values indicating high accuracy of the new method. In addition to that the results 
obtained proved no interference occurred from excipients already found in their 
pharmaceutical preparations. 
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        Table 19 Diclofenac sodium accuracy results for the proposed SIA methods 
Conc. of Diclofenac 
µg/ml 
Absorbance Recovery (%) Acceptance 
Criteria 
30 
30 
30 
60 
60 
60 
90 
90 
90 
0.235 
0.216 
0.226 
0.360 
0.353 
0.349 
0.497 
0.490 
0.485 
100.77 
98.24 
96.72 
102.33 
97.47 
98.89 
102.35 
100.55 
99.49 
 
Mean (recovery)                                                      :  99.6 
Standard deviation                                                   :  2.01 
Relative standard deviation (RSD)                          : 2.02 % 
98.0–102.0 %
 
< 2 % 
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 Table 20 Results obtained by the SIA and British Pharmacopoeia methods for the analysis 
of Diclofenac sodium in tablets samples 
 
Drug 
 
Supplier 
 
Contents 
(mg) 
Mean recovery ± RSD (%)a 
___________________________________
SIA method      BPc method 
 
tb
 
Olfen-50 
 
Mepha Ltd., 
Aesch-Basel, 
Switzerland 
 
Diclofenac 
sodium 
(50) 
 
 
97.8 ± 1.3              99 ± 0.15 
 
 
 
2.1 
 
 
Olfen-25 
 
Mepha Ltd., 
Aesch-Basel, 
Switzerland 
 
Diclofenac 
sodium 
(25) 
 
 
98.6 ± 1.5              99 ± 0.16 
 
2.2 
 
 
INFLA-BAN  
50 
 
 
The Arab 
Pharmaceutical 
Manufacturing 
Co. Ltd., Sult- 
Jordan 
Diclofenac 
sodium 
(50) 
 
 
98.3 ± 1.8              99.8 ± 0.14 
 
 
1.6 
 
 
INFLA-BAN  
25 
The Arab 
Pharmaceutical 
Manufacturing 
Co. Ltd., Sult- 
Jordan 
Diclofenac 
sodium 
(25) 
 
 
98.8 ± 1.8              99.9 ± 0.14 
 
1.8 
 
 
Retard-100 
 
Dar Al Dawa, 
Na’ur - Jordan 
Diclofenac 
sodium 
(100) 
 
 
99.2 ± 2.0          99.7 ± 0.15 
 
2.0 
 
Divido 
 
 
Tabuk 
Pharmaceutical 
Mfg. Co., 
Tabuk, Saudi 
Arabia 
Diclofenac 
sodium 
(75) 
 
 
98.5  ± 1.6         99.6  ± 0.17 
 
2.1 
a Relative standard deviation for 5 replicates 
b Student t-test values (t Critical = 2.9) 
c British Pharmacopoeia 
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 4.2.3.4   Precision 
The precision of an analytical procedure is the degree of agreement among individual test 
results when the procedure is applied repeatedly to multiple samplings of a homogeneous 
sample. The precision of an analytical procedure is usually expressed as the standard 
deviation or relative standard deviation of a series of measurements. Precision may be a 
measure of either the degree of repeatability (short-term precision) or reproducibility 
(intermediate or long term precision) of the analytical procedure under normal operating 
conditions.  
 
 4.2.3.4.1   Repeatability 
The short term precision for DCS was demonstrated as the relative standard deviation, 
RSD, of nine samples (3 replicates each) of 60.0 µg ml-1 DCS (Table 21). The RSD found 
was 1.1% , a value that lies within the acceptance criteria (<2%).  
Another set of nine samples of DCS was analyzed again according to the optimum 
procedure but at another day (Table 22). The results indicate once again that the 
repeatability of the method is acceptable.  
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               Table 21 Diclofenac sodium repeatability results for the proposed SIA  
               methods 
 
Sample no. Concentration 
(µg/ml) 
Absorbance 
1 
2 
3 
4 
5 
6 
7 
8 
9 
60.0 
60.0 
60.0 
60.0 
60.0 
60.0 
60.0 
60.0 
60.0 
0.364 
0.368 
0.356 
0.366 
0.364 
0.357 
0.363 
0.630 
0.361 
 
Mean                                                :  0.362 
Standard deviation                           : 0.004 
Relative standard deviation (RSD)  : 1.1 % 
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                  Table 22 Diclofenac sodium repeatability results for the proposed SIA  
                   methods 
Sample no. Quantity added (mg ml-1)        Absorbance 
1 
2 
3 
4 
5 
6 
7 
8 
9 
 
60.0 
60.0 
60.0 
60.0 
60.0 
60.0 
60.0 
60.0 
60.0 
 
0.350 
0.355 
0.347 
0.346 
0.345 
0.337 
0.353 
0.352 
0.345 
 Mean                                                            :           0.348 
 Standard deviation                                       :           0.005 
Relative standard deviation (RSD)               :           1.5 % 
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 4.2.3.4.2   Reproducibility 
The intermediate precision for the optimized method was demonstrated by analyzing nine 
DCS samples (3 replicates each) over different days. The results obtained (Table 23) 
indicate a RSD of 1.8% that, also, lies within the acceptable range of precision.   
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 Table 23 Diclofenac sodium precision results for the proposed SIA methods 
Sample no. Concentration 
(mg/ml) 
    Absorbance 
1 
2 
3 
4 
5 
6 
7 
8 
9 
 
60.0 
60.0 
60.0 
60.0 
60.0 
60.0 
60.0 
60.0 
60.0 
0.365 
0.345 
0.347 
0.351 
0.349 
0.350 
0.348 
0.351 
0.343 
Mean                                                                  :             0.350 
Standard deviation                                             :             0.006 
Relative   standard deviation (RSD)                 :             1.8 % 
 
 
 
 
 
 152
  
CONCLUSION 
The SIA is considered as the technique, prime goal to be achieved and demonstrated 
during this work for quantitative assays of two important drugs, that is Ketoconazole and 
Diclofenac sodium.  
 
 The experimental results obtained spurred into the development of two new methods for 
the quantitative assay of the antifungal drug ketoconazole and anti-inflammatory 
Diclofenc Sodium. The methods are suitable for the assay of the drugs in generic forms 
pharmaceutical preparations such as tablet and suspension formulations. 
  
The newly adopted methods have the advantage over the official British Pharmacopoeia 
and other reported standard methods with respect to rapidity, economy automation using 
the latest-state-of-the-art Sequential Injection Analysis (SIA) technology. 
 
Also this new system was successfully used for the optimization of instrumental and 
chemical different parameters such as delay time in the holding coil, flow rate of the 
colored products through the flow cell, concentration of sulfuric acid, concentration of 
potassium permanganate, and concentration of cerium (IV). The optimization was 
achieved utilizing different chemometrics approaches namely, uni-variate, factorial 
design, and MultiSimplex.  
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The optimized SIA methods were applied to the assay of Ketoconazole and Diclofenac 
sodium in tablet forms collected from local dispensaries. The results obtained showed 
good accuracy and precision.                                                                     
 The application of the SIA technique would be of a great advantage to the industrial 
sectors in the kingdom especially those in the pharmaceutical arena.  
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APPENDICES 
 
(I)   OPTIMIZED COMPUTER FLOW PROGRAM USED FOR SIA 
SYSTEM CALIBRATION 
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
Syringe Pump Dispense (microliter) 2000 
Syringe Pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
Valve  port 2   
syringe pump Aspirate (microliter) 100 
syringe pump Delay Until Done  
Syringe Pump Flowrate (microliter/sec) 20 
Valve port 1  
chemical New Sample  
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chemical Name std1 
chemical Quantity 50 
syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
Delay (sec) 1 
Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
Syringe Pump Dispense (microliter) 2000 
Syringe Pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
Valve port 3  
syringe pump Aspirate (microliter) 100 
syringe pump Delay Until Done  
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Syringe Pump Flowrate (microliter/sec) 20 
Valve port 1  
chemical New Sample  
chemical Name std2 
chemical Quantity 100 
syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
Delay (sec) 1 
Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
Syringe Pump Dispense (microliter) 2000 
Syringe Pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
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Valve port 4    
syringe pump Aspirate (microliter) 100 
syringe pump Delay Until Done  
Syringe Pump Flowrate (microliter/sec) 20 
Valve port 1  
chemical New Sample  
chemical Name std3 
chemical Quantity 150 
syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
Delay (sec) 1 
Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning 
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
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Syringe Pump Dispense (microliter) 2000 
Syringe Pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
Valve port 5   
syringe pump Aspirate (microliter) 100 
syringe pump Delay Until Done  
Syringe Pump Flowrate (microliter/sec) 20 
Valve port 1  
chemical New Sample  
chemical Name std4 
chemical Quantity 200 
syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
Delay (sec) 1 
Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
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Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
Syringe Pump Dispense (microliter) 2000 
Syringe Pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
Valve port 6    
syringe pump Aspirate (microliter) 100 
syringe pump Delay Until Done  
Syringe Pump Flowrate (microliter/sec) 20 
Valve port 1  
chemical New Sample  
chemical Name std5 
chemical Quantity 250 
syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
Delay (sec) 1 
Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
 168
  
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
Syringe Pump Dispense (microliter) 2000 
Syringe Pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
Valve port 7    
syringe pump Aspirate (microliter) 100 
syringe pump Delay Until Done  
Syringe Pump Flowrate (microliter/sec) 20 
Valve port 1  
chemical New Sample  
chemical Name unknown 1 
chemical Quantity unknown 
syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
Delay (sec) 1 
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Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
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(II) OPTIMIZED COMPUTER FLOW PROGRAM FOR 
KETOCONAZOLE DETERMINATION 
‘STANDARD 1 
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
Syringe Pump Dispense (microliter) 2000 
Syringe Pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
Valve  port 2   
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
Valve port 3    
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
Syringe Pump Flowrate (microliter/sec) 16.202 
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Valve port 1  
chemical New Sample  
chemical Name std1 
chemical Quantity 60 
syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
Delay (sec) 1 
Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
‘STANDARD 2 
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
Syringe Pump Dispense (microliter) 2000 
Syringe Pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
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Valve  port 2   
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
Valve port 4     
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
Syringe Pump Flowrate (microliter/sec) 16.202 
Valve port 1  
chemical New Sample  
chemical Name std2 
chemical Quantity 90 
syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
Delay (sec) 1 
Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
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‘STANDARD 3 
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
Syringe Pump Dispense (microliter) 2000 
Syringe Pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
Valve  port 2   
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
Valve port 5  
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
Syringe Pump Flowrate (microliter/sec) 16.202 
Valve port 1  
chemical New Sample  
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chemical Name std3 
chemical Quantity 120 
syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
Delay (sec) 1 
Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
‘STANDARD 4 
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
Syringe Pump Dispense (microliter) 2000 
Syringe Pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
Valve  port 2   
syringe pump Aspirate (microliter) 50 
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syringe pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
Valve port 6     
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
Syringe Pump Flowrate (microliter/sec) 16.202 
Valve port 1  
chemical New Sample  
chemical Name std4 
chemical Quantity 150 
syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
Delay (sec) 1 
Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
‘STANDARD 5 
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
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Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
Syringe Pump Dispense (microliter) 2000 
Syringe Pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
Valve  port 2   
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
Valve port 7     
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
Syringe Pump Flowrate (microliter/sec) 16.202 
Valve port 1  
chemical New Sample  
chemical Name std5 
chemical Quantity 180 
syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
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Delay (sec) 1 
Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
‘UNKNOWN  
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
Syringe Pump Dispense (microliter) 2000 
Syringe Pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
Valve  port 2   
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
syringe pump Flowrate (microliter/sec) 100 
Valve port 8  
syringe pump Aspirate (microliter) 50 
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syringe pump Delay Until Done  
Syringe Pump Flowrate (microliter/sec) 16.202 
Valve port 1  
chemical New Sample  
chemical Name std6 
chemical Quantity unknown 
syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
Delay (sec) 1 
Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
 
 
 
 
 
 
 
 179
  
(III)   OPTIMIZED COMPUTER FLOW PROGRAM USED FOR 
DICLOFENAC SODIUM DETERMINATION 
''Run 1 -50 ppm 
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
Syringe Pump Dispense (microliter) 2000 
Syringe Pump Delay Until Done  
'Permanganate 
syringe pump Flowrate (microliter/sec) 100 
Valve  port 2   
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
'Diclofenac 
syringe pump Flowrate (microliter/sec) 100 
Valve port 3    
syringe pump Aspirate (microliter) 50 
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syringe pump Delay Until Done  
Valve port 1  
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Delay (sec) 30 
Syringe Pump Flowrate (microliter/sec) 10 
Valve port 1  
chemical New Sample  
chemical Name std1 
chemical Quantity 15 
syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
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Delay (sec) 1 
Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
''Run 2 -30 ppm 
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
Syringe Pump Dispense (microliter) 2000 
Syringe Pump Delay Until Done  
'Permanganate 
syringe pump Flowrate (microliter/sec) 100 
Valve  port 2   
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
'Diclofenac 
syringe pump Flowrate (microliter/sec) 100 
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Valve port 4  
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
Valve port 1  
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Delay (sec) 30 
Syringe Pump Flowrate (microliter/sec) 10 
Valve port 1  
chemical New Sample  
chemical Name std2 
chemical Quantity 30 
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syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
Delay (sec) 1 
Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
''Run 3 -45 ppm 
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
Syringe Pump Dispense (microliter) 2000 
Syringe Pump Delay Until Done  
'Permanganate 
syringe pump Flowrate (microliter/sec) 100 
Valve  port 2   
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
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'Diclofenac 
syringe pump Flowrate (microliter/sec) 100 
Valve port 5  
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
Valve port 1  
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Delay (sec) 30 
Syringe Pump Flowrate (microliter/sec) 10 
Valve port 1  
chemical New Sample  
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chemical Name std3 
chemical Quantity 45 
syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
Delay (sec) 1 
Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
''Run 4 -60 ppm 
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
Syringe Pump Dispense (microliter) 2000 
Syringe Pump Delay Until Done  
'Permanganate 
syringe pump Flowrate (microliter/sec) 100 
Valve  port 2   
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syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
'Diclofenac 
syringe pump Flowrate (microliter/sec) 100 
Valve port 6  
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
Valve port 1  
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Delay (sec) 30 
Syringe Pump Flowrate (microliter/sec) 10 
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Valve port 1  
chemical New Sample  
chemical Name std4 
chemical Quantity 60 
syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
Delay (sec) 1 
Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
''Run 5 -75 ppm 
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
Syringe Pump Dispense (microliter) 2000 
Syringe Pump Delay Until Done  
'Permanganate 
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syringe pump Flowrate (microliter/sec) 100 
Valve  port 2   
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
'Diclofenac 
syringe pump Flowrate (microliter/sec) 100 
Valve port 7  
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
Valve port 1  
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
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Delay (sec) 30 
Syringe Pump Flowrate (microliter/sec) 10 
Valve port 1  
chemical New Sample  
chemical Name std5 
chemical Quantity 75 
syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
Delay (sec) 1 
Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
''Run 6 -90 ppm 
syringe pump Flowrate (microliter/sec) 100 
Syringe Pump Valve In  
Syringe Pump Fill  
Syringe Pump Delay Until Done  
Valve port 1  
Syringe Pump Valve Out  
Syringe Pump Dispense (microliter) 2000 
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Syringe Pump Delay Until Done  
'Permanganate 
syringe pump Flowrate (microliter/sec) 100 
Valve  port 2   
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
'Diclofenac 
syringe pump Flowrate (microliter/sec) 100 
Valve port 8  
syringe pump Aspirate (microliter) 50 
syringe pump Delay Until Done  
Valve port 1  
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
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Syringe Pump Aspirate (microliter) 5 
Syringe Pump Dispense (microliter) 5 
Delay (sec) 30 
Syringe Pump Flowrate (microliter/sec) 10 
Valve port 1  
chemical New Sample  
chemical Name std6 
chemical Quantity 90 
syringe pump Dispense (microliter) 1500 
Spectrometer Reference Scan  
Delay (sec) 1 
Spectrometer Absorbance Scanning  
Syringe Pump Delay Until Done  
Spectrometer Stop Scanning  
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